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 ABSTRACT 
Syntheses of azepinoindole alkaloids cimitrypazepine, fargesine and  
hyrtioreticulins C & D 
Ganesh Ghimire 
 
The Watanabe-Cenini-Söderberg reductive N-heterocyclization has emerged as a powerful tool 
for the synthesis of a variety of functionalized indoles. Söderberg’s elaboration of this 
methodology has been utilized as a late-stage cyclization protocol for the synthesis of 
azepinoindole alkaloids, a class of natural products characterized by an azepane skeleton fused 
with an indole ring. Short syntheses of the naturally occurring azepino[5,4,3-cd]indole alkaloids, 
cimitrypazepine, fargesine, and the diastereomeric hyrtioreticulins C & D have been completed 
starting from commercially available tetra-substituted benzene derivatives. The key 
azepinoindole core in each case was assembled via an intramolecular Mizoroki-Heck reaction 
followed by a Watanabe-Cenini-Söderberg reductive N-heterocyclization. Synthesis of 
aurantioclavine using a similar strategy is currently underway. 
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1.1 Introduction of Indole 
 Indole (1), also called benzopyrrole, is an aromatic heterocyclic compound in which a 
pyrrole ring is fused to a benzene ring (Figure 1).   
Figure 1: Structure and Numbering of Indole 
 
1 
 After their discovery in 1860's by Baeyer and coworkers,1 indole-based compounds are 
perhaps the most highly studied organic molecules due to their widespread application in 
industries, pharmaceuticals, agrochemicals, dyes, perfumes and dietary supplements (Figure 2).2 
Indoles are considered ‘Privileged structures’ in drug discovery as they are capable of binding to 
multiple receptors with high affinity.3,4  
Figure 2: Indole Containing Drugs and Chemicals 
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The interest in indole chemistry was more intensified after 1930’s when it was discovered 
that many natural products and bioactive molecules contain indoles as their core structures. The 
indole nucleus is embedded in many biological systems including the essential amino acid 
tryptophan, the neurotransmitter serotonin, and the mammalian hormone melatonin. Tryptophan 
is a structural constituent of many proteins as well as the biosynthetic precursor of serotonin, 
which in turn serves as the precursor of melatonin (Scheme 1). Serotonin plays a critical role in 
neuronal cell formation and maintenance, sleep, cognition, appetite, and mood, whereas 
melatonin is a natural bioregulator that induces and maintains sleep.5,6  
Scheme 1: Biosynthesis of Melatonin 
 
 Tryptophan is also the biogenetic precursor of many indole alkaloids. Naturally occurring 
indole alkaloids are constantly getting more attention from the scientific community due to their 
intriguing structure and biological activity. Many endeavors are driven by structural complexity 
4 
 
and their potential as drug candidates. Development of advanced isolation and characterization 
techniques has made their investigation convenient. As a result, many new indole alkaloids are 
reported annually. Synthetic attempts toward these complex indole structures may lead to 
reaction discovery and development. A number of methods have been reported as established 
routes for the preparation of indole and its analogs.7 Among the synthetic routes, there are quite a 
few transition metal- catalyzed or -mediated methods of indole synthesis.8,9,10 Among the 
plethora of methodologies used for indole synthesis, the Watanabe-Cenini- Söderberg reductive 
N-heterocyclization11 has emerged as a powerful tool for indole synthesis, which will be 
discussed in the following section.  
1.2 Watanabe-Cenini- Söderberg Reductive N-Heterocyclization 
Although first discovered by Watanabe,12 the reductive N-heterocyclization of o-
nitrostyrenes to give indoles was extensively elaborated by Söderberg group establishing the 
methodology as a powerful synthetic method (Scheme 2). Although not unprecedented, the 
Söderberg method provides a number of significant improvements over previously reported 
conditions such as low temperature, mild reaction conditions and ease of work-up, because the 
only by-product formed is carbon dioxide.13  
Scheme 2: Watanabe and Söderberg Reductive Heterocyclization 
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Söderberg’s method has been successfully applied to the synthesis of a number of indole 
analogs including tryptophan derivatives,14 bicyclic heteroaromatics, 15 carbazole alkaloids, 16 
mushroom metabolites, 17 and various natural products. 18-25 Through a detailed optimization 
study of the reaction conditions, it was observed that the Pd(dba)2-dppp-1,10-phenanthroline 
system using DMF as solvent at 120 °C under 6 atm of carbon monoxide (Scheme 3) was highly 
applicable to late stage indolization during many natural products syntheses.22-25  
Scheme 3: Söderberg Reductive N-Heterocyclization Optimized for Late Stage Indolization 
in Natural Products Synthesis 
 
         
1.3 3,4-Fused Azepinoindoles 
Azepinoindoles refer to the organic compounds in which a seven-membered ring 
containing nitrogen is fused with indole core. Azepinoindoles fused at 1,2-, 2,3- and 3,4- position 
of the pyrrole ring have been reported. Azepinoindoles are named according to the following 
scheme based on the fusion position of the azepine-ring with indole.26 The nitrogen atom of the 
azepine ring is designated atom 1 and proceeds towards the pyrrole portion of the molecule 
6 
 
(Figure 3). The bonds in the pyrrole ring are named a, b, c and d to indicate where the azepine 
ring is fused. The numbering of fused atoms starts from the number of the atom closest to the 
pyrrole nitrogen. 
Figure 3: Naming of Azepinoindoles   
 
 
Naturally occurring azepino[5,4,3-cd]indoles have been isolated from diverse natural 
sources (Figure 4). This group of alkaloids include aurantioclavine isolated from the fungus 
Penicillium aurantiovirens,27 clavicipitic acid from the fungus Claviceps fusiformis,28 the 
diastereomeric alkaloids hyrtireticuline C and D from the marine sponge Hyrtios reticulatus,29 
fargesine from the roots and stems of Evodia fargesii,30 cimitrypazepine from the roots and 
rhizomes of black cohosh, Cimicifuga racemosa,31 and bisindole alkaloid hyrtiazepine from 
Hyrtios erectus.32 
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Figure 4: Naturally Occurring Azepino[5,4,3-cd]indoles. 
 
1.4 Strategies Towards the Synthesis of Azepino[5,4,3-cd]indoles  
Among the naturally occurring indoles, azepino[5,4,3-cd]indoles have been considered 
attractive synthetic targets because of their biological activities and intrinsic structural 
complexity. A variety of synthetic strategies have been used to prepare the azepino[5,4,3-
cd]indole ring system and the most prevalent are functional group manipulations of 3,4-
disubstituted indoles to form the azepine ring. The formation of the carbon-nitrogen bond b is the 
most commonly used approach in total synthesis33,34 although the formation of carbon-nitrogen 
bond c35and carbon-carbon bonds a36,37and d38have been employed (Figure 5). The assembly of 
both the pyrrole and azepine rings onto a functionalized benzene ring is more unusual but 
sequential f-e-b,39 b then f,40 and e then f 41bond formations have been described. The latter 
methodologies offer perhaps more flexible routes to a variety of functionalized analogs 
compared to the use of a preassembled indole ring as the starting material. 
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Figure 5: Ring Disconnections Employed in Syntheses of Naturally Occurring 
Azepino[5,4,3-cd]indoles 
 
The ensuing sections will discuss various strategies used to synthesize 3,4-fused 
azepinoindoles.   
1.4.1 Syntheses via ‘a’ Bond Formation 
Cyclization at 4-position of indole via ‘a’ bond formation has been employed to complete 
the syntheses of various azepinoindoles. Bartoccini et al.42used rhodium(I) catalyzed 
intramolecular imine hydroarylation of pinacolboranate ester 8 to synthesize clavicipitic acid 12 
(Scheme 4). This one pot procedure allowed the regioselective introduction of the prenyl side 
chain at C-4 of tryptophan, forming a C−C bond at the least nucleophilic position (C-4) of the 
indole core, instead of at the highly nucleophilic positions C-2 and C-3. 
Scheme 4: Synthesis of Clavicipitic Acid by Bartoccini et al. 
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Use of base-promoted Pictet–Spengler reaction of in-situ formed iminium ion 
intermediate 15 to construct the azepine ring was pioneered by Yamada et al. The authors 
developed a one-pot procedure for the assembly of the azepino[5,4,3-cd]indole ring system 
through the reaction of N-benzylserotonin 13 (Scheme 5) or tryptophan with aldehydes and used 
this approach to provide a concise synthesis of aurantioclavine 17 and other hyrtios alkaloids.43 
Scheme 5: Syntheses Using Pictet-Spengler Reaction 
 
 
1.4.2 Syntheses via ‘b’ Bond Formation 
In 2009, Xu et al.44 obtained the azepinoindole via Lewis acid mediated SN2’ reaction. It 
was an accidental observation that they obtained cyclized product during removal of boc group 
10 
 
of 19 by magnesium perchlorate. Even though the exact mechanism has not been explored, it 
was postulated that Mg acting as Lewis acid activates the allylic -OH group and facilitates the 
SN2’ reaction to complete the synthesis of clavicipitic acid 21 (Scheme 6). 
Scheme 6: Xu’s Synthesis of Clavicipitic Acid 
 
 
 
Ito et al.45 used an ortho-selective α-hydroxyalkylation of indole 23 followed by 
intramolecular imination of resulting ketone 25 to assemble the azepine ring (Scheme 7) and 
finally complete the synthesis of hyrtiazepine 27.  
Scheme 7: Synthesis of Hyrtiazepine by Ito et al. 
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Later, a similar intramolecular reductive amination of ketone using NaBH(OAc)3 at room 
temperature was utilized to complete the synthesis of clavicipitic acid by Tahara and coworkers 
(Scheme 8).46 
Scheme 8: Synthesis of Clavicipitic Acid by Tahara et al. 
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Liu and coworkers47 performed olefination at the C4 position of tryptophan derivative 32 
via a palladium catalyzed C-H activation and finally a silver acetate catalyzed allylic amination 
to complete the synthesis of clavicipitic acid 36 (Scheme 9). 
Scheme 9: Liu’s Synthesis of Clavicipitic Acid  
 
 
 
1.4.3 Syntheses via ‘c’ Bond Formation 
Stoltz group48 in 2008 used Mitsunobu reaction of substituted indole 37 to assemble the 
azepine ring (Scheme 10) to complete the synthesis of aurantioclavine 39. 
Scheme 10: Synthesis of Aurantioclavine by Stoltz et al.  
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Similarly, Ellman et al.49 utilized the imine precursor 40 which underwent Grignard 
addition sequence to afford azepinoindole core to complete the synthesis of aurantioclavine 43 
(Scheme 11).  
Scheme 11: Synthesis of Aurantioclavine by Ellman et al. 
 
 
 
1.4.4 Cyclization at 3-Position of Indole 
Cheng and coworkers50utilized chiral phosphoric acid catalyzed asymmetric Pictet-
Spengler type reaction to close the azepine ring forming the azepinoindole. The method was used 
successfully to obtain many azepinoindole analogs with high enantioselectivity (Scheme 12). 
 
 
 
14 
 
Scheme 12: Chiral Phosphoric Acid Catalyzed Cyclization 
 
 
 
Kumar et al.51 reported the synthesis of azepinoindoles by post-Ugi indium(III)-mediated 
regioselective intramolecular hydroarylation reaction (Scheme 13). 
Scheme 13: Indium Triflate Catalyzed Cyclization 
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Xu and coworkers52 described diversity-oriented synthesis via allylic alkylation reactions 
where iridium catalyzed pathway provided azepinoindoles selectively (Scheme 14). 
Scheme 14: Iridium Catalyzed Cyclization 
 
 
 
1.4.5 Synthesis via Sequential ‘e’ and ‘f’ or ‘b’, ‘e’ and ‘f’ Bond Formation 
The strategies described above, and many others utilize preassembled indole unit as the 
starting material. Sequential cyclizations forming the ‘e’ and ‘f’ bonds or ‘b’, ‘e’ and ‘f’ bonds 
have also been reported. The latter methodologies employ functionalized benzene rings as the 
starting materials and, probably offer more flexible routes to a variety of functionalized analogs.  
In 2013, Jia and coworkers41 reported intramolecular Larock indolization reaction to 
synthesize azepinoindole nucleus. Starting from tetrasubstituted iodoaniline 57 as cyclization 
precursor, the authors revealed a very efficient way to synthesize 3,4-fused azepinoindoles 
directly. The method was successfully used to complete the synthesis of fargesine 59.  
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Scheme 15: Intramolecular Larock Indole Synthesis 
 
Söderberg et al.25 used the stepwise cyclization strategy to form the azepine ring via 
intramolecular Mizoroki-Heck reaction followed by N-heterocyclization to form the 
azepinoindole. The strategy was successfully used for the total synthesis of cimitrypazepine, 
fargesine and Hyrtioreticulins C & D.  
Scheme 16: Söderberg’s Sequential Cyclization 
 
  Recently, Nemoto et al.53described the synthesis of 3,4-fused tricyclic indole structure 
based on the platinum-catalyzed intramolecular Friedel-Crafts-type C–H coupling–allylic 
amination cascade and used it to complete the total synthesis of fargesine (Scheme 17). 
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Compared to Jia et al. who used tetrasubstituted iodoaniline derivative, they used trisubstituted 
aniline derivative for the synthesis. 
Scheme 17: Nemoto’s Synthesis of Fargesine 
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2.1 Introduction to Cimitrypazepine and Fargesine 
 Cimitrypazepine was extracted from the roots of black cohosh Cimicifuga racemosa in 
2012. The roots/rhizomes of black cohosh have traditionally been used by Native Americans for 
treating a variety of medical conditions such as colds, rheumatism as well as for alleviating 
menopausal symptoms such as hot flashes. Because of the risks associated with hormone 
replacement therapy, black cohosh preparations have become popular dietary supplements 
among women seeking alternative treatments for menopausal complaints. Nikolić and 
coworkers31 confirmed the azepinoindole structure of cimitrypazepine by comparing the mass 
spectrometric fragmentation of natural and synthetic samples of the alkaloid. 
Traditional Chinese folk medicine has employed the fruits of Evodia fargesii as a cough 
suppressant as well as an analgesic for stomach aches. Three new N-oxide alkaloids were 
isolated from the roots and stems of the plant in 2006 (Figure 6).30 Among those, the tricyclic N-
oxide alkaloid fargesine 66 was identified to be an azepino[5,4,3-cd]indole. Even though the 
components from the extracts of Evodia species have been found to be biologically active, 
biological activity of fargesine has not been studied so far.  
Figure 6: Structure of N-Oxide Alkaloids from Evodia fargesii 
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2.2 Literature Synthesis of Cimitrypazepine and Fargesine 
2.2.1 Nikolić’s Synthesis of Cimitrypazepine 
Nikolić et al.31 reported the synthesis of cimitrypazepine 71 using a Pictet-Spengler type 
cyclization of N-methylserotonin 69 and formaldehyde as the key azepine ring-forming step. The 
authors reported 1H-NMR data and also compared the mass spectrometric data of the synthetic 
cimitrypazepine with the natural compound. 
Scheme 18: Biomimetic Synthesis of Cimitrypazepine 
 
2.2.2 Jia’s Synthesis of Fargesine 
In 2013, Jia and coworkers41 developed an efficient strategy to synthesize fused tricyclic 
indoles from substituted 2-halogenanilines via the palladium-catalyzed intramolecular Larock 
indolization process and used it to complete the first total synthesis of fargesine (Scheme 19). 
The reductive amination between benzaldehyde and primary amine afforded the secondary 
amine adduct 74. Protection of both hydroxy and amine functional groups using Boc2O followed 
by reduction of nitro group provided the cyclization precursor 75 in good yield. The key Larock 
indolization of aniline 75 gave the tricyclic azepinoindole which after stepwise deprotection, N-
methylation and N-oxidation sequence provided fargesine 78. 
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Scheme 19: Jia’s Synthesis of Fargesine 
 
2.2.3 Nemoto’s Synthesis of Cimitrypazepine and Fargesine 
Cimitrypazepine and fargesine were also synthesized recently by Nemoto and 
coworkers53 using a platinum-catalyzed intramolecular Friedel-Crafts type C-H coupling-allylic 
amination cascade (Scheme 20). The cyclization precursor 83 was synthesized using two 
consecutive Mitsunobu reactions followed by Zn-mediated reduction of nitro group. The 
platinum-catalyzed intramolecular Friedel-Crafts type C-H coupling-allylic amination cascade 
provided the tricyclic indoline 84, which after TFA mediated isomerization, Na-naphthalide 
reduction, N-methylation and debenzylation sequence gave cimitrypazepine 85. Finally, m-
CPBA mediated N-oxidation of cimitrypazepine afforded fargesine 86.   
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Scheme 20: Nemoto’s Synthesis of Cimitrypazepine and Fargesine 
 
2.3 Short Syntheses of Cimitrypazepine and Fargesine 
 The unique structure of fargesine featuring an azepino[5,4,3-cd]indole core and N-oxide 
function in the azepine ring inspired us to commence a synthetic study. The goal of the synthesis 
was to highlight the use of the Watanabe-Cenini-Söderberg palladium-catalyzed reductive N-
heterocyclization as the key step to assemble the indole ring at the later stage of natural products 
synthesis.   
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2.3.1 Retrosynthetic Analysis 
 The intriguing structure of cimitrypazepine and fargesine allowed us to propose a 
relatively concise synthetic route (Scheme 21).  It was envisioned that fargesine 87 could result 
from N-oxidation of cimitrypazepine 88.  Cimitrypazepine 88, in turn, could be achieved by N-
methylation of the azepine ring of N-protected amine 89. The indole core of 89 could be 
prepared through Watanabe-Cenini-Söderberg reductive N-heterocyclization of nitroaromatic 90.  
Intramolecular Heck reaction of terminal alkene 91 would give the desired reductive N-
heterocyclization precursor 90.  The terminal alkene 91 could be prepared by a reductive 
amination of known aldehyde 93 and 4-amino-1-butene 92.   
Scheme 21: Proposed Retrosynthetic Outline for Cimitrypazepine and Fargesine 
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2.3.2 Results and Discussion 
6-Hydroxy-2-iodo-3-nitrobenzaldehyde (94),54 readily prepared from commercially 
available 4-hydroxy-2-iodo-1-nitrobenzene, served as the starting point for the synthesis of both 
cimitrypazepine and fargesine (Scheme 22). Reductive amination of 94 using 4-amino-1-butene 
and sodium borohydride afforded the expected product 95 in good yield.  
Scheme 22: Reductive Amination of 6-Hydroxy-2-iodo-3-nitrobenzaldehyde  
 
The next goal was to assemble the azepine ring from 95. Treatment of compound 95 
under typical Heck conditions, using a palladium diacetate – tri(o-tolyl) phosphine catalyst 
system in triethylamine as the solvent and stirring at 125 °C, did not furnish any observable 
amount of the anticipated bicyclic product.  This was probably due to the coordination of -NH 
and -OH group with the catalyst system inhibiting the desired coordination with the alkene 
moiety. Therefore, both the hydroxy and the amino group in 95 were protected by reaction with 
di-t-butyldicarbonate ((Boc)2O) in the presence of 4- (N, N-dimethylamino)pyridine (DMAP). 
The starting material 95 was cleanly converted into a single new compound (by TLC). The 
anticipated di-protected compound 97 was the only aromatic compound seen in the 1 H NMR 
spectrum of the crude reaction mixture. However, upon purification by chromatography on silica 
gel, the O-deprotected compound 98 was isolated as the major product, in addition to 97 
(Scheme 23). It was speculated that the -O-Boc group readily falls off during purification under 
standard silica gel chromatography conditions. However, it was possible to increase the 
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percentage of di-protected compound 97 upon treatment of 98 using the same reaction 
conditions.  The N-Boc group was intended to serve a dual purpose, lowering the coordination 
ability of the nitrogen, at times a problem in intramolecular Heck reactions, and as a source of 
the azepine N-methyl group after reduction. In our case, protection of the amine was crucial for 
the Heck reaction to occur.55 
Scheme 23: Synthesis of O-Boc and N-Boc Protected Amines 97 and 98. 
 
  Intramolecular Heck reactions were attempted using both 97 and 98 in order to evaluate 
the need for O-protection. Di-protected compound 97 was completely consumed after 3.5 h as 
observed by TLC. Work up and careful purification by chromatography gave four different 
products (Scheme 24).  Two 2-benzazepines, the di-O, N-Boc protected compound 101 and the 
N-Boc protected compound 102, were isolated as the major products. In addition, minor amounts 
of two 2-benzazocines (103 and 104) differing in the position of the unsaturation in the eight-
membered ring were also obtained. The latter two compounds had lost the O-Boc group during 
the reaction or upon purification of the crude reaction mixture. Intramolecular Heck reactions 
affording mixtures of 2-benzazepines and 2-benzazocines have previously been reported.56 It 
should be noted that the Heck reaction of 97 was unpredictable and varying ratios and yields of 
products were obtained from seemingly identical reaction conditions and concentrations. The 
result shown in Scheme 24 represents the highest isolated yield of 101 and 102 obtained in 
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several cyclizations of 97. In comparison to the reaction of 97, cyclization of 98 was more 
consistent but gave a slightly lower isolated yield of the 2-benzazepine product 102 (relative to 
101+102, 66%) and a slightly higher yield of 2-benzazocine 103. 
Scheme 24. Synthesis of 2-Benzazepines 101 and 102 and Benzazocines 103 and 104. 
 
 
 
Palladium catalyzed reductive N-heterocyclization of 101 using a 
bis(dibenzylideneacetone)palladium-1,3-bis(diphenylphosphino)propane-1,10-phenanthroline 
catalyst system in the presence of carbon monoxide (pCO = 6 atm, 120 °C) in N,N-
dimethylformamide, furnished the di-N,O-protected azepino[5,4,3-cd]indole 105 in addition to 
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the N-protected analogue 106 in 79% total yield (Scheme 25). Treatment of compound 102 using 
the same reagents and reaction conditions also gave 106 in a somewhat lower isolated yield. 
Finally, upon treatment of 105 with sodium bis(2-methoxyethoxy) aluminum hydride (Red-Al) 
in toluene at reflux, the O-Boc group was removed and the N-Boc group of 105 was reduced to a 
methyl group affording 88 (cimitryptazepine). Alkaloid 88 was also isolated in excellent yield 
from Red-Al reduction of 106. All analytical data including 1H and 13C NMR, IR, HRMS, and 
melting point of synthetic cimitryptazepine were identical to the literature values of the 
compound isolated and synthesized by Nikolic et al.31 
Scheme 25. N-Heterocyclization and Reduction to Give Cimitryptazepine 88 
 
Direct oxidation of the azepine-nitrogen of 88 using m-chloroperbenzoic acid (m-CPBA) 
in dichloromethane 57or hydrogen peroxide – ammonium hydrogen carbonate in water did not 
furnish fargesine; instead intractable mixtures were obtained in all attempted reactions.  In place 
of a direct oxidation of 88 to fargesine, we decided to intercept an intermediate reported in the 
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previous synthesis of fargesine.41 Thus, cimitrypazepine 88 was O-Boc-protected to give 107 in 
excellent yield. This compound has previously been oxidized and deprotected using m-CPBA 
and sodium hydroxide, respectively, to afford fargesine 87.   
Scheme 26. Synthesis of Fargesine 87 
 
 
2.4 Conclusions 
 A concise linear total syntheses of the naturally occurring azepino[5,4,3-cd]indoles, 
cimitrypazepine and fargesine has been completed utilizing an intramolecular Heck reaction 
forming the azepine ring and Watanabe-Cenini- Söderberg reductive N-heterocyclization 
building the pyrrole ring of the indole as key steps. The flexibility offered by our intramolecular 
Heck reaction to form the azepine ring and late stage reductive N-heterocyclization opens the 
possibility of using the strategy in other synthesis of other azepinoindole alkaloids. 
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3.1 Introduction to Hyrtioreticulins C & D 
  
 Marine sponges of the genus Hyrtios are known to be rich sources of structurally diverse 
natural products such as alkaloids, sesterterpenes and macrolide with significant cytotoxic and 
antimicrobial activities.  Out of six hyrtioreticuline analogs (A-F, 108-113) isolated so far from 
the Hyrtios species (Figure 7),58,59 Hyrtioreticulins A and B inhibited ubiquitin-activating 
enzyme (E1). Hyrtioreticulins C & D were isolated as diastereomeric azepinoindole alkaloids 
from the marine sponge Hyrtios reticulatus, which was collected in Indonesia by Tsukamoto and 
co-workers.58 Even though the detailed biological study of hyrtioreticulins C & D has not been 
reported, these azepinoindole alkaloids are attractive synthetic targets as they resemble 
aurantioclavine and clavicipitic acid. The first synthesis of hyrtioreticulins C and D was reported 
by Abe and Yamada43c in 2017 wherein a Pictet-Spengler cyclization was employed as the key 
step. 
Figure 7: Hyrtioreticulins A-F (108-113) Isolated From Hyrtios reticulatus 
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3.2 Previous Synthesis of Hyrtioreticulins C & D 
3.2.1 Abe and Yamada Synthesis 
In 2017, Abe and Yamada43c reported the first total syntheses of hyrtioreticulins C & D. 
Their biomimetic synthesis featured an unprecedented base-promoted C-4 Pictet-Spengler 
reaction of tryptophan. Microwave irradiation of 5-hydroxytryptophan 114 with 3 equivalents of 
acetaldehyde under basic condition selectively formed azepino[5,4,3-cd]indoles having trans 
isomer as the major product (Scheme 27). Basic hydrolysis of azepinoindoles 115 and 116 gave 
hyrtioreticulins C & D (117 and 118), respectively. 
Scheme 27: First Synthesis of Hyrtioreticulins C & D 
 
3.3 Total Syntheses of Hyrtioreticulins C & D 
 Abe and Yamada synthesis utilized the preformed tryptophan which possessed a pre-
installed indole ring as the starting material. Our goal was to elaborate the use of Watanabe-
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Cenini-Söderberg reductive N-heterocyclization reaction as an efficient tool for a late stage 
indole ring formation.  
3.3.1 Retrosynthetic Analysis 
 The resemblance of hyrtioreticulins with cimitrypazepine and fargesine previously 
synthesized in our lab25 prompted us to propose a relatively similar synthetic route (Scheme 28). 
In order to explore the versatility of our terminally unsaturated N-tethered cyclization precursor, 
our initial synthetic design was inspired from the work of Zhang et al. that utilized an efficient 
rhodium(III)-catalyzed intramolecular hydroarylation of alkynes.60 The method would serve as 
an alternative route for installing the key azepine ring and thereby provide a straight forward 
route, after reductive N- heterocyclization, to the tricyclic azepinoindole. 
It was envisioned that the hyrtioreticulins 119 could result from protecting group manipulation of 
120. The indole core of 120 could be prepared through Watanabe-Cenini-Söderberg reductive N-
heterocyclization of nitroaromatic 121.  It was speculated that the rhodium(III)-catalyzed 
intramolecular hydroarylation of alkynes proposed by Zhang and coworkers could be used for 
terminal alkyne 122 to give the desired reductive cyclization precursor 121. The terminal alkyne 
122 could be prepared by reductive amination of known acetophenone derivative 124 and 
propargyl glycine methyl ester 123.  
Scheme 28: Proposed Retrosynthetic Outline for Hyrtioreticulins 
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3.3.2 Results and Discussion 
The forward synthesis of hyrtioreticulins started from commercially available 2-hydroxy-5-
nitroacetophenone. Under the optimized conditions, transimination of in situ generated primary 
ketimine of 2-hydroxy-5-nitroacetophenone 125 with amine 126 followed by sodium 
borohydride reduction of the corresponding imine gave the new racemic amine 127 in 33% 
overall yield (Scheme 29). 
Scheme 29: Indirect Reductive Amination to Form 127  
 
Amine 127 was then subjected to Rh(III)-catalyzed intramolecular annulation as 
described by Zhang et al.60 Unfortunately, the desired 2-benzazepine 129 was not detected even 
after varied reaction conditions; instead an undesired cyclization product 128 was isolated as the 
sole product in 42% yield (Scheme 30). The product 128 was also isolated in about 30% yield 
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under similar reaction conditions without the rhodium catalyst. The isolated product probably 
resulted from an intramolecular hydroamination of terminal alkyne 127 favoring a 5-endo-dig 
cyclization.61 It was also expected that the unprotected secondary amine in 127 could coordinate 
with the metal and prevent the otherwise possible C-H activation by the catalyst thereby favoring 
the formation of 128.   
Scheme 30: Undesired Cyclization of 127  
 
These results prompted us to revisit our synthetic design where the key benzazepine 
could be obtained using Mizoroki-Heck reaction of terminal alkene as evidenced by our 
synthesis of cimitrypazepine and fargesine.25 This allowed us to modify our retrosynthetic 
analysis as shown in scheme 31. It was envisioned that the hyrtioreticulins 130 could result, after 
the removal of protecting groups, from Watanabe-Cenini-Söderberg reductive N-
heterocyclization of benzazepine 131. Intramolecular Mizoroki-Heck reaction of terminal alkene 
132 would give the desired reductive N-heterocyclization precursor 131.  The terminal alkene 
132 could be prepared by reductive amination of known acetophenone derivative 133 and allyl 
glycine methyl ester 134.   
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Scheme 31: Revised Retrosynthetic Outline for Hyrtioreticulins 
 
The alternative synthesis was started from nitration of commercially available 2-hydroxy-
6-methoxyacetophenone 135 according to Cushman et al.62 The authors reported only 138 as the 
nitration product from 135. But after careful purification of the crude reaction mixture by 
chromatography, we were able to isolate three products 136, 137 and 137 (Scheme 32).  
Scheme 32: Nitration of 2-Hydroxy-6-methoxyacetophenone 
 
The next goal was to use the desired 138 to construct the Heck reaction precursor. It 
should be noted here that direct reductive amination of 138 with allyl glycine methyl ester 134 
using a series of reagents (NaBH4, NaBH3CN, TiCl4 etc.) did not produce the desired product. 
The ketone 138 was then subjected to trans-imination conditions by treating it with excess 
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ammonia solution in methanol followed by the amino acid methyl ester before reducing the 
corresponding imine with sodium borohydride. The product obtained was a racemic mixture 140 
in 78% overall yield (Scheme 33).  
Scheme 33: Trans-imination of 2-Hydroxy-6-methoxy- 3-nitroacetophenone with L-
allylglycine Methyl Ester 
 
Intramolecular Heck reaction of 140 using one of the standard catalyst systems, 
palladium diacetate – tri(o-tolyl)phosphine – triethyl amine (125 °C)25,55 did not furnish any 
observable amount of the anticipated bicyclic product.  Eventually, we decided to adopt an 
alternative method recently reported by Zhou et al.63 The authors described a highly 
regioselective intermolecular Mizoroki-Heck reaction of aryltriflates with aliphatic olefins 
leading to the formation of 1,1-disubstituted alkene. To the best of our knowledge, the catalyst 
system developed by Zhou et al. has not been evaluated in intramolecular reactions.  
Even though partial separation of the diastereomers of 140 was possible, they were 
directly reacted with trifluoromethanesulfonic anhydride (Tf2O) and pyridine with the 
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speculation that the corresponding triflates could be separated during purification of the crude 
product. As expected, the corresponding triflates 142 and 143 were readily separated during 
purification of the crude reaction mixture with excellent isolated yields (Scheme 34). 
Scheme 34: Triflation of Racemic Phenol 140 
 
When the triflates 142 and 143 were subjected to intramolecular Mizoroki-Heck reaction 
under Zhou’s conditions using bis(dibenzylidenacetone)palladium (Pd(dba)2), 
bis(diphenylphosphino)ferroccene (dppf), and urotropin in N,N-dimethylacetamide (DMA), the 
corresponding 2-benzazepines 144 and 145 were isolated as the only products albeit in moderate 
yields (Scheme 35). It should be noted here that cyclization of 142 gave a slightly higher isolated 
yield than 143.  
Scheme 35: Synthesis of 2-Benzazepines 144 and 145. 
 
    Watanabe-Cenini-Söderberg reductive N-heterocyclization of 144 and 145 using a 
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bis(dibenzylideneacetone)palladium-1,3-bis(diphenyl)phosphinopropane- 1,10-phenanthroline 
catalyst system in the presence of carbon monoxide (pCO=6 atm, 120 °C) in N,N-
dimethylformamide, furnished the azepino[5,4,3-cd]indoles 146 and 147 in 44% and 43% yield 
(Scheme 36), respectively.  
Scheme 36: N-heterocyclization to Give Azepinoindoles 146 and 147. 
 
Finally, removal of the protecting groups in 146 and 147 would give hyrtioreticulins C & 
D. Demethylation using BBr3 in DCM has been reported to be successful in similar substrates in 
the total synthesis of hyrtiazepine by Ito et al.45 Treatment of 146 and 147 with BBr3 under 
reported and varied temperature and solvent conditions did not furnish hyrtioreticulins; instead 
intractable mixtures were obtained in all attempted reactions. This prompted us to think about 
alternative protecting groups to replace the methoxy group. We anticipated that benzyl protecting 
group would be a better choice as it could be easily removed by reduction over Pd/C.43d,45 
Thus, the synthesis was attempted again starting from nitration of 2-hydroxy-6-
benzylacetophenone according to Cushman et al.62 which gave two products 149 and 150 in 4% 
and 45% yield respectively (Scheme 37).  
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Scheme 37: Nitration of 2-Hydroxy-6-benzylacetophenone 
 
Imination trans-imination of the desired 150 with allylgycine methyl ester under the same 
conditions described above afforded the cis and trans products 153 and 152 which were readily 
separated by chromatography with 34% and 45% yields respectively. Treatment of 152 and 153 
with triflic anhydride in presence of pyridine afforded the corresponding triflates 145 and 155 in 
excellent yields (Scheme 38). 
Scheme 38: Imination, Trans-imination and Triflation to Give 154 and 155 
 
With the triflates 154 and 155 in hand, intramolecular Mizoroki-Heck reaction under 
Zhou’s conditions provided 2-benzazepines 158 and 159 smoothly as expected. Watanabe-
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Cenini-Söderberg reductive N-heterocyclization of the nitroaromatic compounds 158 and 159 
afforded the benzyl protected analogs of azepinoindoles 160 and 161 in 73% and 59% 
respectively (Scheme 39).  
Scheme 39: Intramolecular Heck Reaction and Reductive N-heterocylization 
 
Finally, reduction of azepinoindoles 160 and 161 using Pd/C at 1 atm H2 removed the 
benzyl group as expected to give hyrtioreticulins methyl esters 164 and 165 (Scheme 40). These 
compounds have previously been hydrolyzed using 10% NaOH/H2O in methanol to afford 
hyrtioreticulins C & D.43c  
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Scheme 40: Synthesis of Hyrtioreticulins C & D 
 
3.4 Conclusions 
A concise linear total syntheses of the naturally occurring azepino[5,4,3-cd]indole 
diastereomers, hyrtioreticulins C & D has been completed. An imination, trans-imination, a 
regio-selective intramolecular Mizoroki-Heck reaction and a Watanabe-Cenini- Söderberg 
reductive N-heterocyclization are the key steps in the syntheses. 
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4.1 Introduction to Aurantioclavine     
Aurantioclavine 168 was first isolated from the fungus Penicillium aurantiovirens in 
1981 by Kozlovskii and coworkers.27 This molecule and a related alkaloid, clavicipitic acid 169 
isolated from the fungus Claviceps fusiformis, are proposed to be biosynthetic intermediates of 
the complex polycyclic alkaloids of the communesin family (Figure 8).64 Members of this family 
display notable bioactivities, including insecticidal properties and cytotoxicity toward leukemia 
cell lines.   
Figure 8: Structural Relationship of Aurantioclavine with Communesins 170 
 
4.2 Notable Syntheses of Aurantioclavine 
After the first total synthesis of aurantioclavine 168 in 1985 by Somei et al.,34a several 
racemic and enantioselective syntheses have been reported to date.34,35,49 Stoltz and coworkers48 
reported the first enantioselective synthesis and determination of the absolute stereochemistry. 
4.2.1 First Synthesis of Aurantioclavine by Somei 
Somei and coworkers reported the first total synthesis of aurantioclavine (Scheme 41).34a 
The starting 3-formylindole 171 was readily converted into nitroethylindole 172. An 
intermolecular Heck reaction of 4-iodoindole 172 with allylic alcohol 173 provided 174. Finally, 
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an intramolecular reductive amination using Zn-Hg/HCl afforded racemic aurantioclavine 175 
(Scheme 41).  
Scheme 41: Somei’s Synthesis of Aurantioclavine 
 
4.2.2 First Enantioselective Synthesis by Stoltz 
Stoltz and coworkers48 reported the first enantioselective synthesis of (-)-aurantioclavine 
(Scheme 42). The key reactions were a palladium-catalyzed oxidative kinetic resolution65 and an 
intramolecular Mitsunobu reaction to install the azepine ring.    
The starting 4-formylindole 176 was readily converted into racemic diol 178 by the 
addition of organolithium 177. A palladium-catalyzed oxidative kinetic resolution in presence of 
chiral ligand (-)-sparteine gave 179 with 96% ee albeit in low isolated yield. The diol 179 was 
converted to 181 over five steps which underwent intramolecular Mitsunobu reaction to afford 
azepinoindole 182 in excellent yield, which after deprotection of tosyl and nosyl groups gave (-)-
aurantioclavine. Absolute configuration of (-)-aurantioclavine was confirmed by X-ray analysis.  
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Scheme 42: Stoltz Synthesis of Aurantioclavine 
 
4.2.3 Most recent Synthesis by Takemoto 
The most recent scalable synthesis of aurantioclavine was reported by Takemoto and 
coworkers (Scheme 43).66 The hydroxyethylindole 184 was converted to 185 using a Mitsunobu 
reaction.  Removal of Boc group followed by a Suzuki-Miyaura coupling with boronic ester 186 
introduced the allylic alcohol unit at the C-4 position. A desilylation using TBAF to afford 188, 
and a Mg(ClO4)2 mediated allylic amination of 188 provided the N-tosylated azepinoindole 189, 
which after removal of the tosyl group gave aurantioclavine 190.  
 
 
46 
 
Scheme 43: Concise and Scalable Synthesis by Takemoto 
 
 4.3 Attempted Synthesis of Aurantioclavine 
 Our comparatively short strategy to synthesize azepinoindoles comprised of three 
important steps: reductive amination, intramolecular Mizoroki-Heck reaction, and Watanabe-
Cenini-Söderberg reductive N-heterocyclization. Since aurantioclavine shares a common 
azepinoindole framework like fargesine and hyrtioreticulins, we anticipated that similar strategy 
could be used for its synthesis. 
4.3.1 Retrosynthetic Analysis 
 The resemblance of aurantioclavine with the natural products previously synthesized in 
our lab prompted us to propose a relatively similar synthetic route (Scheme 44). Aurantioclavine 
possesses a 2-methylpropene substituent at the C-6 position of the ring. Therefore, our synthetic 
strategy was focused primarily on synthesizing a cyclization precursor having pre-installed 2-
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methylpropene substituent. It was envisioned that aurantioclavine 191 could result from 
Watanabe-Cenini -Söderberg reductive N-heterocyclization of nitroaromatic 192. Intramolecular 
Mizoroki-Heck reaction of 193 would give the desired reductive N-heterocyclization precursor 
192. The terminal alkene 193 could be prepared by reductive amination of enone derivative 194 
and known 4-amino-1-butene 195. The enone 194 could be obtained by dehydration of aldol 
adduct 196 which, in turn, could result from a crossed-aldol reaction between known 2-hydroxy-
3-nitroacetophenone 197 and acetone 198.   
Scheme 44: Proposed Retrosynthetic Outline of Aurantioclavine 
 
4.3.2 Results and Discussion 
The synthesis of aurantioclavine began with the crossed aldol reaction between 2-
hydroxy-3-nitroacetophenone 199 and acetone using LHMDS as a base at -78 °C which 
furnished the expected aldol product 200 in 72% isolated yield. Dehydration of compound 200 in 
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the presence of TFAA and pyridine at 0 °C went smoothly to afford the enone 201 in excellent 
yield (Scheme 45). 
Scheme 45: Aldol Reaction and Dehydration of the Aldol Product 
 
Attempts of reductive amination of 201 with 4-amino-1-butene under various conditions 
yielded only the undesired retro-aldol product. With a view that dehydration step could be 
performed after reductive amination, some reductive amination protocols found in the literature 
were also tried with the ketone 200. Unfortunately, formation of retro-aldol products was even 
more pronounced in reactions when 200 was used in reactions. Additionally, attempts to protect 
the phenolic group of 201 with triflic anhydride and pyridine were also unsuccessful. Therefore, 
the hydroxy group of 201 was protected using p-methoxybenzyl chloride (PMBCl) to give 203 in 
good yield (Scheme 46).  
Scheme 46: Protection of Phenol Using PMBCl 
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The PMB-protected ketone 203 finally underwent TiCl4-mediated reductive amination 
with 4-amino-1-butene at -78 °C in the presence of sodium borohydride as reducing agent to give 
the desired amine 205, albeit without the protecting group (Scheme 47). This unexpected 
removal of p-methoxybenzyl group during the reductive amination procedure was beneficial in 
the sense that it could save the deprotection step.  
Scheme 47: Reductive Amination of Enone 203  
 
The terminal alkene 205, after converting the hydroxy group into triflate, would undergo 
intramolecular Mizoroki-Heck reaction as evidenced by our previous syntheses (vide supra). 
Attempts to convert 205 into a triflate as cyclization precursor using triflic anhydride and 
pyridine at varying temperature conditions were unsuccessful as all our endeavors resulted in 
decomposed products. 
4.3.3 Conclusions 
A short synthesis of aurantioclavine is currently underway. A crossed-aldol reaction and 
a TiCl4-mediated reductive amination served as an expedient route to the Heck reaction 
precursor 205. Further optimization is deemed necessary to perform the Heck reaction, which 
would, in turn, lead to the azepinoindole alkaloid aurantioclavine.   
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Overall Conclusion 
Short synthetic schemes leading to naturally occurring azepino[5,4,3-cd]indole alkaloids 
cimitrypazepine, fargesine and diastereomeric hyrtioreticulins C & D have been developed. A 
terminal alkene-tethered tetra-substituted nitrobenzene analogue served as a key intermediate for 
a sequential formation for the azepine ring and the pyrrole ring of the natural products.  
The intramolecular Mizoroki-Heck reaction using one of the standard catalyst systems, 
palladium diacetate – tri(o-tolyl)phosphine – triethyl amine (125 °C) provided, in addition to the 
desired seven-membered ring, the eight-membered rings as minor products. Alternatively, 
intramolecular cyclization of related substrates using bis(dibenzylideneacetone)palladium 
(Pd(dba)2), bis(diphenylphosphino)ferroccene (dppf), and urotropin in N,N-diemethylacetamide 
(DMA) provided a seven membered rings as the single product. Thus, our results suggested that 
the synthesis of both 1,1-disubstituted and 1,2-disubstituted alkenes can be obtained from the 
same substrate simply by modifying the catalyst system.  
The Watanabe-Cenini-Söderberg reductive N-heterocyclization served as an efficient late stage 
cyclization protocol for the syntheses of above mentioned azepinoindole alkaloids. The catalyst 
system Pd(dba)2-dppp-1,10-phenanthroline using DMF as solvent at 120 
°C under 6 atm of 
carbon monoxide was successfully utilized in all of the four syntheses to afford the desired 
indole ring, which further elaborated its synthetic utility for the synthesis of a variety of 
functionalized indoles.  
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General Procedures. NMR spectra were determined in CDCl3 at 600 MHz (
1H NMR) and 150 
MHz (13C NMR), 400 MHz (1H NMR) and 100 MHz (13C NMR), or at 270 MHz (1H NMR) and 
67.5 MHz (13C NMR).  The chemical shifts are expressed in δ+ values relative to SiMe4 (0.0 
ppm, 1H and 13C) or CDCl3 (77.0 ppm, 
13C) internal standards.  1H-1H coupling constants are 
reported as calculated from spectra, thus a slight difference between Ja,b and Jb,a is usually 
observed.  Tetrahydrofuran (THF) was distilled from sodium benzophenone ketyl prior to use.  
Hexanes and ethyl acetate were distilled from calcium hydride. Anhydrous acetonitrile, benzene, 
dichloromethane, 1,4-dioxane, N,N-dimethylformamide, and toluene were used as received. 
Chemicals prepared according to literature procedures have been footnoted the first time used; 
all other reagents were obtained from commercial sources and used as received. All reactions 
were performed under a nitrogen atmosphere in oven-dried glassware. Solvents were removed 
from reaction mixtures and products on a rotary evaporator at water aspirator pressure unless 
otherwise stated.  Chromatography was performed on silica gel 60 (40-63 µm, Sorbtech).  
Melting points (uncorrected) were recorded directly from products obtained by chromatography.  
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5.1 Supporting Information for Chapter 2: Cimitrypazepine and Fargesine 
 
 
 
 
 
To a stirred solution of 6-hydroxy-2-iodo-3-nitrobenzaldehyde (94), (200 mg, 0.682 
mmol) and 4-amino-1-butene (48.5 mg, 0.682 mmol) in methanol (2.1 mL) at ambient 
temperature was added NaBH4 (51.6 mg, 1.36 mmol). The mixture was stirred at ambient 
temperature for 1 h. Water (21 mL) was added and the resulting mixture was extracted with 
EtOAc (3×25 mL). The combined organic layers were dried (MgSO4), filtered and solvents were 
removed under reduced pressure. The crude product was purified by chromatography 
(CHCl3/MeOH/NH4OH, 100:10:1) affording 95 (166 mg, 0.477 mmol, 70%) as a yellow solid. 
Analytical data for 95: mp= 158-160 °C; 1H NMR (400 MHz, CDCl3) δ 7.65 (d, J= 8.4 Hz, 1H), 
7.0 (br s, 2H) 6.80 (d, J= 9.2 Hz, 1H), 5.77 (ddt, J= 17.6, 10.4, 6.4, Hz, 1H), 5.17 (d, J= 18.0 Hz, 
1H), 5.16 (d, J= 9.2 Hz, 1H), 4.32 (s, 2H), 2.79 (t, J= 6.8 Hz, 2H), 2.35 (q, J= 6.4 Hz, 2H); 13C 
NMR (100 MHz, CDCl3) δ 162.7, 146.3, 134.6, 126.1, 125.5, 118.2, 116.8, 92.8, 58.5, 47.2, 
33.2; IR (ATR) 2954, 2874, 2174, 1524, 1453, 1338, 1243, 829, 727 cm-1; HRMS (ESI) calcd 
for C11H14IN2O3 (M+H
+) 249.0049, found 249.0049. 
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To a stirred solution of compound 95 (166 mg, 0.477 mmol) in acetonitrile (MeCN, 4.8 
mL) was added di-t-butyldicarbonate ((Boc)2O, 208 mg, 0.954 mmol) and 4-(N,N-
dimethylamino)pyridine (DMAP, 11.8 mg, 0.095 mmol) at ambient temperature. The mixture 
was stirred for 18 h. The solvent was removed under reduced pressure and the crude product was 
dissolved in water (20 mL). The mixture was extracted with EtOAc (3×20 mL). The combined 
organic layers were dried (MgSO4), filtered, and the solvents were removed under reduced 
pressure. The crude product was purified by chromatography (hexanes/EtOAc, 98:2) to give, in 
order of elution, 97 (82 mg, 0.150 mmol, 31%) as a pale-yellow oil and 98 (119 mg, 0.265 
mmol, 56%) as a pale yellow solid.  Analytical data for 97: 1H NMR (400 MHz, CDCl3, 50 °C) δ 
7.58 (d, J= 9.2 Hz, 1H), 7.29 (d, J= 9.2 Hz, 1H), 5.77 (ddt, J= 17.2, 10.0, 6.8, Hz, 1H), 5.01 (d, 
J= 18.8 Hz, 1H), 4.97 (d, J= 10.0 Hz, 1H), 4.75 (s, 2H), 3.06 (br s, 2H), 2.22 (q, J= 7.2 Hz, 2H), 
1.56 (s, 9H), 1.47 (s, 9H); 13C NMR (100 MHz, CDCl3, 60 °C, mixture of rotamers) δ 155.1, 
153.5, 151.9, 150.6, 135.9, 135.3, 124.1, 123.4, 116.6, 93.4, 85.1, 80.1, 50.5, 45.7, 32.7, 28.7, 
28.5,28.3, 27.9, 27.7; IR (ATR) 3082, 2978, 2936, 1760, 1693, 1123 cm-1; HRMS (ESI) calcd 
for C21H30IN2O7 (M+H
+) 549.1098, found 549.1104. 
Analytical data for 98: mp=105-106 °C; 1H NMR (400 MHz, CDCl3) δ 7.67 (d, J= 9.2 Hz, 1H), 
6.93 (d, J= 8.8 Hz, 1H), 5.75  (ddt, J= 17.2, 10.0, 6.8, Hz, 1H), 5.07-5.01 (m, 2H), 4.82 (s, 2H), 
3.42 (t, J= 7.2 Hz, 2H), 2.34 (pent, J= 7.6 Hz, 2H), 1.50 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 
160.7, 159.2, 147.6, 134.6, 128.2, 127.4, 118.1, 117.6, 95.7, 83.0, 51.5, 46.5, 32.9, 28.5; IR 
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(ATR) 3078, 2980, 2937, 1737, 1641, 1525, 1442 cm-1; HRMS (ESI) calcd for C16H22IN2O5 
(M+H+) 449.0573, found 449.0578. 
 
 
A solution of 97 (749 mg, 1.37 mmol), Pd(OAc)2 (15.3 mg, 0.068 mmol), and tri(o-
tolyl)phosphine (TTP, 41.4 mg, 0.136 mmol) in triethylamine (TEA, 6.8 mL) was heated at 125 
°C (2 h). After 2 h, the reaction mixture was cooled to ambient temperature, diluted with ethyl 
acetate (10 mL) and filtered (Celite). The filtrate was evaporated to remove the solvents. 
Purification of the crude product by chromatography (hexanes/EtOAc, 98:2 then 8:2) gave, in 
order of elution, 101 (250 mg, 0.595 mmol, 43%) as pale yellow oil, compound 103 (10 mg, 
0.031 mmol, 2%) as pale yellow solid, 104 (36 mg, 0.112 mmol, 8%) as yellow oil, and 102 (102 
mg, 0.318 mmol, 23%) as yellow solid. 
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A solution of 98 (132 mg, 0.295 mmol), palladium diacetate (Pd(OAc)2, 3.3 mg, 0.015 
mmol), and tri(o-tolyl)phosphine (TTP, 9.0 mg, 0.030 mmol) in triethylamine (TEA, 1.5 mL) 
was heated at 125 °C for 6 h. The reaction mixture was cooled to ambient temperature, diluted 
with EtOAc (10 mL) and filtered (Celite). The solvent was removed under reduced pressure from 
the filtrate. Purification of the crude product by chromatography (hexanes/EtOAc, 95:5 then 
90:10) gave, in order of elution, 103 (12 mg, 0.037 mmol, 13%) as yellow oil and compound 102 
(55 mg, 0.172 mmol, 58%) as yellow solid. 
Analytical data for 101: 1H NMR (600 MHz, CDCl3, -52 °C, mixture of rotamers) δ 7.73 (d, J= 
9.0 Hz, 1H), 7.70 (d, J= 8.9 Hz, 1H), 7.26 (d, J= 8.9 Hz, 1H), 7.23 (d, J= 8.9 Hz, 1H), 5.27 (s, 
2H), 4.98 (s, 1H), 4.97 (s, 1H), 4.47 (br s, 2H), 4.21 (br s, 2H) 3.25 (br s, 2H), 3.10 (br s, 2H), 
2.60 (br s 2H), 2.52 (br s, 2H), 1.60 (s, 9H), 1.58 (s, 9H), 1.44 (s, 9H), 1.40 (s, 9H); 13C NMR 
(100 MHz, CDCl3, -52
 °C, mixture of rotamers) δ 154.2, 154.0, 151.1, 150.9, 149.7, 149.2, 
146.9, 146.7, 143.4, 143.2, 139.9, 139.4, 131.2, 123.6, 123.2, 122.3, 121.1, 116.9, 116.8, 84.6, 
80.5, 79.9, 50.1, 49.9, 44.4, 44.0, 36.3, 35.6, 28.1, 28.0, 27.4, 27.3; IR (ATR) 2981, 2936, 2359, 
1760, 1694, 1228, 1132 cm-1; HRMS (ESI) calcd for C16H22IN2O5 (M+H
+) 421.1975, found 
421.1977.  
Analytical data for 102: mp= 137-138 °C; 1H NMR (400 MHz, CDCl3, 45 °C) δ 7.62 (d, J= 8.8 
Hz, 1H), 6.91 (d, J= 8.8 Hz, 1H), 5.32 (s, 1H), 5.10 (s, 1H), 4.31 (br s, 2H), 3.77 (br s, 2H), 2.50 
(t, J= 5.6 Hz, 2H), 1.43 (s, 9H); 13C NMR (100 MHz, CDCl3, 45 °C) δ 158.2, 156.7, 143.2, 
142.0, 140.1, 124.9, 124.7, 81.7, 51.1, 44.6, 37.0, 28.3; IR (ATR) 3221, 2981, 2933, 1695, 1652, 
1577, 1520, 1457, 1423, 1307 cm-1; HRMS (ESI) calcd for C16H21N2O5 (M+H
+) 321.1450, found 
321.1451.  
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Analytical data for 103: 1H NMR (600 MHz, CDCl3) δ 10.40 (s, 1H), 7.78 (d, J= 8.4 Hz, 1H), 
6.89 (d, J= 9.0 Hz, 1H), 6.36 (dt, J= 10.1, 8.4 Hz, 1H), 5.83 (dt, J= 10.1, 7.2 Hz, 1H), 4.69 (s, 
2H), 4.14 (d, J= 7.2 Hz, 2H), 3.74 (d, J= 7.8 Hz, 2H), 1.43 (s, 9H); 13C NMR (150 MHz, CDCl3) 
δ 161.3, 157.6, 142.7, 138.8, 136.6, 127.5, 126.5, 125.4, 117.5, 82.3, 46.7, 46.2, 29.4, 28.5; IR 
(ATR) 3099, 2978, 2934, 1711, 1641, 1519, 1423, 1264 cm-1; HRMS (ESI) calcd for 
C16H21N2O5 (M+H
+) 321.1450, found 321.1446.  
Analytical data for 104: mp 154-155 °C; 1H NMR (600 MHz, CDCl3) δ 11.52 (s, 1H), 8.10 (d, 
J= 9.6 Hz, 1H), 7.03 (d, J= 10.8 Hz, 1H), 6.96 (d, J= 9.6 Hz, 1H), 6.14 (dt, J= 11.4, 8.4 Hz, 1H), 
4.89 (br s, 1H), 4.09 (br s, 1H), 3.76 (br s, 1H), 2.71 (br s, 1H), 2.47 (br s, 1H), 1.81 (br s, 1H), 
1.49 (s, 9H); 13C NMR (150 MHz, CDCl3) δ 162.7, 158.2, 140.1, 134.6, 131.4, 128.5, 127.6, 
124.4, 117.3, 82.9, 43.9, 41.4, 28.6, 28.4; IR (ATR) 2980, 2934, 2871, 2720, 2632, 1641, 1520, 
1449 cm-1; HRMS (ESI) calcd for C16H21N2O5 (M+H
+) 321.1450, found 321.1446.  
 
 
A solution of 101 (102 mg, 0.243 mmol), bi(dibenzylidenacetone)palladium (13.9 mg, 
0.024 mmol), 1,3-bis(diphenylphosphino)propane (10 mg, 0.024 mmol), and 1,10-
phenanthroline (8.7 mg, 0.048 mmol) in anhydrous N,N-dimethylformamide (1.3 mL), in an 
ACE-Glass pressure tube fitted with a pressure head, was saturated with carbon monoxide (4 
cycles to 6 atm of CO). The reaction mixture was stirred under CO (6 atm) at 120 °C for 20 h. 
The mixture was cooled to ambient temperature, diluted with EtOAc (5 mL), and washed with 
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brine (3×5 mL). The organic phase was dried (MgSO4) and filtered. The solvent was removed 
under reduced pressure and the resulting residue was purified by chromatography 
(hexanes/EtOAc, 9:1 then 4:1) to afford, in order of elution, 105 (47 mg, 0.12 mmol, 50%) as a 
pale yellow solid and 106 (20 mg, 0.069 mmol, 29%) as a pale yellow solid.  
A solution of 102 (48.0 mg, 0.150 mmol), bis(dibenzylideneacetone)-palladium (6.0 mg, 
0.010 mmol), 1,3- bis(diphenylphosphino)propane (4.3 mg, 0.010 mmol), and 1,10-
phenanthroline (3.8 mg, 0.021 mmol) in anhydrous N,N-dimethylformamide (0.6 mL), in an 
ACE-Glass pressure tube fitted with a pressure head, was saturated with carbon monoxide (4 
cycles to 6 atm of CO). The reaction mixture was stirred under CO (6 atm) at 120 °C for 72 h. 
The mixture was cooled to ambient temperature, diluted with EtOAc (3 mL), and washed with 
brine (3×3 mL). The organic phase was dried (MgSO4) and filtered. The solvent was removed 
under reduced pressure and the resulting residue was purified by chromatography 
(hexanes/EtOAc, 4:1) to afford 106 (26 mg, 0.09 mmol, 60%) as a pale yellow solid.  
Analytical data for 105 from a mixture of rotamers: mp= 153−155 °C; 1H NMR (400 MHz, 
CDCl3) δ 8.20 (br s, 1H), 7.16 (d, J= 8.8 Hz, 0.5H), 7.15 (d, J= 9.2 Hz, 0.5H), 6.97 (s, 1H), 6.90 
(d, J= 8.8 Hz, 1H), 4.90 (s, 1H), 4.82 (s, 1H), 3.76 (t, J= 6.0 Hz, 1H), 3.71 (t, J= 4.8, 1H), 3.14 (t, 
J= 5.6 Hz, 1H), 3.10 (t, J= 4.8 Hz, 1H), 1.58 (s, 4.5H), 1.55 (s, 4.5H), 1.46 (s, 4.5H), 1.39 (s, 
4.5H); 13C NMR (100 MHz, CDCl3) δ 155.3, 155.0, 152.9, 152.8, 140.9, 140.5, 135.0, 134.8, 
125.9, 125.8, 124.4, 124.2, 122.8, 122.6, 116.4, 116.3, 115.5, 115.2, 110.1, 109.9, 83.2, 83.2, 
80.0, 79.8, 49.1, 48.3, 47.8, 28.8, 28.6, 28.0, 27.9, 27.7, 26.6; IR (ATR) 3315, 2978, 2935, 1752, 
1693, 1669, 1140 cm-1; HRMS (ESI) calcd for C21H29N2O5 (M+H
+) 389.2076, found 389.2078. 
Analytical data for 106: mp= 186-188 °C; 1H NMR (400 MHz, CDCl3, 60°C) δ 7.82 (br s, 1H), 
7.06 (d, J= 8.4 Hz, 1H), 6.96 (s, 1H), 6.68 (d, J= 8.4 Hz, 1H), 4.93 (s, 2H), 3.77 (br s, 2H), 3.14 
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(br s, 2H), 1.45 (s, 9H); 13C NMR (100 MHz, CDCl3, mixture of rotamers) δ 155.0, 146.0, 145.7, 
131.8, 126.1, 125.9, 122.2, 122.0, 116.9, 113.8, 113.4, 112.0, 111.6, 109.4, 79.2, 79.1, 49.0, 48.9, 
48.4, 48.0, 40.4, 40.2, 40.0, 39.8, 39.6, 28.5, 28.4, 27.5, 26.7; IR (ATR) 3335, 2972, 1665, 1582, 
1367, 1165 cm-1; HRMS (ESI) calcd for C16H21N2O3 (M+H
+) 289.1552, found 289.1552. 
 
 
To a solution of 105 (110 mg, 0.283 mmol) in anhydrous toluene (28 mL) under a 
nitrogen atmosphere was added sodium bis(2-methoxyethoxy)aluminumhydride (in toluene ∼3.5 
M, 1.9 mL, 6.65 mmol) drop wise. The mixture was stirred at 110 °C for 3 h and then allowed to 
cool to ambient temperature. Brine (56 mL) was added, and the mixture was extracted with 
EtOAc (3×60 mL). The organic phases were combined, dried (MgSO4), and filtered. The solvent 
was removed under reduced pressure and the residue was purified by chromatography 
(EtOAc/MeOH, 9:1) to give 88 (42 mg, 0.21 mmol, 74%) as yellow paste.  
To a solution of 106 (218 mg, 0.756 mmol) in a mixture of toluene (70 mL) and 
tetrahydrofuran (5 mL) under a nitrogen atmosphere was added sodium bis(2-
methoxyethoxy)aluminumhydride (in toluene ∼3.5 M, 5.07 mL, 17.7 mmol) drop wise. The 
mixture was stirred at 110 °C for 4 h and then allowed to cool to ambient temperature. Brine 
(150 mL) was added, and the mixture was extracted with EtOAc (3×150 mL). The organic 
phases were combined, dried (MgSO4), and filtered. The solvent was removed under reduced 
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pressure and the resulting residue was purified by chromatography (EtOAc/MeOH, 9:1) to give 
88 (145 mg, 0.717 mmol, 95%) as a yellow paste.  
Analytical data for 88: 1H NMR (400 MHz, CD3OD) δ 7.08 (d, J= 8.8 Hz, 1H), 7.00 (s, 1H), 
6.67 (d, J= 8.8 Hz, 1H), 4.26 (s, 2H), 3.22 (t with further fine splittings, J= 5.2 Hz, 2H), 3.12 (t 
with further fine splittings, J= 5.6 Hz, 2H), 2.68 (s, 3H); 13C NMR (100 MHz, CD3OD) δ 148.9, 
132.9, 127.0, 124.5, 113.4, 112.5, 110.9, 107.5, 60.6, 57.8, 44.9, 24.4; IR (ATR) 3284, 2913, 
1704, 1583, 1437, 1363, 789 cm-1; HRMS (ESI) calcd for C12H15N2O2 (M+H
+) 203.1184, found 
203.1182. 
 
To a stirred solution of 88 (20 mg, 0.099 mmol) in MeCN (1.0 mL) was added DMAP 
(1.3 mg, 0.010 mmol) at ambient temperature. The mixture was cooled to 0 °C and (Boc)2O 
(23.7 mg, 0.108 mmol) as a solution of MeCN (0.5 mL) was added in portions. The resulting 
mixture was stirred at 0 °C for 6 h. The solvent was removed under reduced pressure and the 
crude product was purified by chromatography (CH2Cl2/MeOH, 20:1) to afford 107 (25 mg, 
0.083 mmol, 84%) as yellow oil.  1H NMR and 13C NMR data were in accordance with literature 
value. HRMS (ESI) calcd for C17H23N2O3 (M+H+) 303.1709, found 303.1708. 
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5.2 Supporting Information for Chapter 3: Hyrtioreticulins C & D 
 
 
A solution of NH4OH and MeOH (1:1, v/v) (1.7 mL) was added dropwise to 2-hydroxy-
3-nitroacetophenone 126 (1.825 g, 10.07 mmol) at ambient temperature. The resulting mixture 
was stirred for 2 h and the solvents were removed under reduced pressure to obtain yellow solid. 
The crude imine was dissolved in dichloromethane (50 mL), and (S)-2-amino-4-pentynoic acid 
methyl ester hydrochloride (2.45 g, 14.95 mmol) and triethylamine (1.51 g, 14.95 mmol) were 
added. The mixture was stirred at ambient temperature for 21 h. Solvents were removed under 
reduced pressure and the crude product was dissolved in methanol (50 mL). To the stirred 
mixture at ambient temperature was added NaBH4 (575 mg, 14.95 mmol) in one portion. The 
resulting mixture was stirred for 2 h at ambient temperature. The volatiles were removed under 
reduced pressure and the crude product was purified by chromatography (DCM/MeOH/NH4OH, 
100:2:1) to afford 127 as an inseparable mixture of diastereomers (1.041 g, 3.56 mmol, 36% 
overall) as yellow solid.  
Analytical data for 127: mp = 87-88 °C; 1H NMR (400 MHz, CDCl3) (as a mixture of 
diastereomers) δ 11.85 (br s, 1H) 11.75 (br s, 1H), 8.09 (t with further splitting, J= 2.8 Hz, 1H), 
8.06 (t with further splitting, J= 3.2 Hz, 1H), 7.95 (d, J= 2.8 Hz, 1H), 7.88 (d, J= 2.8 Hz, 1H), 
6.88 (d, J= 9.2 Hz, 1H), 6.87 (d, J= 9.2 Hz, 1H), 4.18 (q, J= 6.8 Hz, 1H), 3.99 (q, J= 6.8 Hz, 1H), 
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3.82 (s, 3H), 3.77 (s, 3H), 3.56 (m, 1H), 3.38 (m, 1H), 2.72 (m, 6H), 2.16 (t, J= 2.4 Hz, 1H), 2.12 
(t, J= 2.4 Hz, 1H), 1.53 (d, J= 2.8 Hz, 3H), 1.52 (d, J= 3.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
(as a mixture of diastereomers) δ 172.3, 171.7, 163.7, 163.6, 140.6, 140.6, 126.5, 126.2, 125.5, 
125.4, 125.0, 124.4, 117.8, 117.8, 77.8, 73.0, 72.8, 57.9, 57.9, 56.8, 55.5, 55.1, 55.0, 53.0, 29.9, 
23.7, 22.7, 21.7, 21.3; IR (ATR) 3326, 2943, 2229, 2117, 1736, 1544, 1452, 1094, 925 cm-1; 
HRMS (ESI) calcd for C14H17N2O5 (M+H
+) 293.1137, found 293.1131  
 
In an ACE-Glass pressure tube, 127 (102 mg, 0.349 mmol), pivalic acid (178 mg, 1.745 
mmol), t-amyl alcohol (3.6 mL), and pentamethylcyclopentadienylrhodium(III) chloride dimer 
([Rh(C5Me5)Cl2]2) (5.4 mg, 0.009 mmol) were added respectively. To the stirred mixture was 
added silver hexafluoroantimonate [AgSbF6] (12.0 mg, 0.035 mmol) and the pressure tube was 
capped tightly. The resulting mixture was stirred at 120 °C for 4 h. The reaction mixture was 
cooled at ambient temperature and filtered through a pad of silica gel. Solvents were removed 
under reduced pressure from the filtrate and the crude product was purified by chromatography 
(MeOH/DCM, 4:96) to afford 128 (46 mg, 0.15 mmol, 43%) as a grey solid.  
Analytical data for 128: mp= 74-75 °C; 1H NMR (400 MHz, CDCl3) δ 8.01 (dd, J= 9.2, 2.8 Hz, 
2H), 7.97 (d, J= 2.8 Hz, 1H), 6.83 (d, J= 9.2 Hz, 1H), 5.41 (d, J= 3.6 Hz, 1H), 4.08 (q, J= 7.2 Hz, 
1H), 3.76 (s, 3H), 3.54 (dd, J= 10.2, 6.0 Hz, 1H), 2.25 (m, 4H), 1.58 (d, J= 6.8 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 173.6, 159.1, 141.1, 124.4, 124.1, 123.7, 117.6, 88.2, 62.2, 52.5, 
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50.5, 30.9, 25.9, 24.6; IR (ATR) 3327, 2243, 2229, 2071, 1739, 1599, 1498, 1360, 1241, 1094, 
925 cm-1. 
 
2-Hydroxy-6-methoxyacetophenone (3.32 g, 20.0 mmol) was dissolved in glacial acetic 
acid (20 mL) and fuming nitric acid (2.0 mL) was added dropwise. The reaction mixture was 
stirred in a round-bottomed flask equipped with a drying tube (CaC12) at room temperature for 
40 min, and then at 50 °C for 18 h. The solvents were removed under reduced pressure, and 
water (80 mL) was added. The mixture was extracted with EtOAc (3×80 mL). The combined 
organic layers were dried (MgSO4), filtered and solvents were removed under reduced pressure. 
The crude product was purified by chromatography (EtOAc/hexane, 2:8) affording, in the order 
of elution, 136 (321 mg, 1.23 mmol, 6%) as a yellow solid and 137 (369 mg, 1.44 mmol, 7%) as 
yellow solid and 138 (1.35 g, 6.40 mmol, 32%) as a yellow solid.  
Analytical data for 136: mp = 68-69 °C; 1H NMR (400 MHz, CDCl3) δ 13.32 (s, 1H), 8.06 (d, J= 
9.6 Hz, 1H), 6.81 (d, J= 9.2 Hz, 1H), 3.97 (s, 3H), 2.78 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
204.7, 167.5, 157.9, 134.8, 132.5, 114.9, 114.1, 63.2, 32.4; IR (ATR) 3091, 2957, 1942, 1631, 
1592, 1336, 1297, 1224, 1100, 791 cm-1; HRMS (ESI) calcd for C9H10NO5 (M+H
+) 212.0559, 
found 212.0556. 
Analytical data for 137: mp= 70-71 °C; 1H NMR (400 MHz, CDCl3) δ 11.62 (s, 1H), 8.85 (s, 
1H), 4.00 (s, 3H), 2.63 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 198.1, 157.7, 156.2, 135.2, 129.1, 
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126.5, 125.1, 64.4, 32.1; IR (ATR) 3210, 2958, 2155, 1790, 1713, 1587, 1530, 1125, 960, 665 
cm-1; HRMS (ESI) calcd for C9H9N2O7 (M+H
+) 257.0410, found 257.0398. 
Analytical data for 138: mp= 94-95 °C; 1H NMR (400 MHz, CDCl3) δ 12.44 (s, 1H), 8.20 (d, J= 
10.8 Hz, 1H), 6.57 (d, J= 9.6 Hz, 1H), 3.98 (s, 3H), 2.61 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
202.0, 164.0, 156.2, 130.4, 129.6, 115.7, 102.5, 65.5, 32.6; IR (ATR) 3008, 2970, 1738, 1442, 
1366, 1217, 1229, 1109 cm-1; HRMS (ESI) calcd for C9H10NO5 (M+H
+) 212.0559, found 
212.0556. 
 
 
A solution of NH4OH and MeOH (1:1, v/v) (20 mL) was added dropwise to 138 (973 mg, 
4.61 mmol) at ambient temperature. The resulting mixture was stirred for 12 h and the solvents 
were removed under reduced pressure to obtain yellow solid. This crude imine was dissolved in 
dichloromethane (10 mL), and (S)-2-amino-4-pentenoic acid methyl ester hydrochloride (1.53 g, 
9.22 mmol) and triethylamine (466 mg, 4.61 mmol) were added. The mixture was stirred under 
reflux for 12 h. Solvents were removed under reduced pressure and the crude product was 
dissolved in methanol (20 mL). To the stirred mixture at ambient temperature was added NaBH4 
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(261 mg, 6.91 mmol) in one portion. The resulting mixture was stirred for 2h at ambient 
temperature. The solvent was removed under reduced pressure and the crude product was 
purified by chromatography (DCM: MeOH: NH4OH, 100:2:1) to afford 140 as a mixture of 
diastereomers (1.16 g, 3.58 mmol, 78% overall) as yellow solid.  
Analytical data for 140 as a mixture of diastereomers: mp = 104-106 °C; 1H NMR (400 MHz, 
CDCl3) δ 8.00 (d, J= 9.2 Hz, 1H), 7.96 (d, J= 9.6 Hz, 1H), 6.45 (d, J= 8.8 Hz, 1H), 6.42 (d, J= 
9.6 Hz, 1H), 5.73 (m, 1H), 5.61 (m, 1H), 5.13 (m, 4H), 4.54 (q, J= 7.2 Hz, 1H), 4.37 (q, J= 7.2 
Hz, 1H), 3.91 (s, 3H), 3.85 (s, 3H), 3.75 (s, 3H), 3.49 (s, 3H), 3.35 (t, J= 6.4 Hz, 1H), 3.29 (t, J= 
6.0 Hz, 1H), 2.44 (m, 4H), 1.44 (d, J= 3.6 Hz, 3H), 1.42 (d, J= 4.0 Hz, 3H); 13C NMR (151 
MHz, CDCl3) δ 173.8, 173.7, 163.0, 162.0, 155.2, 154.9, 133.0, 131.9, 131.2, 129.7, 126.5, 
126.0, 119.4, 118.4, 118.3, 115.7, 102.7, 101.6, 77.2, 77.0, 76.8, 58.8, 58.4, 56.1, 56.0, 52.1, 
51.6, 50.1, 47.9, 37.4, 36.8, 20.4, 19.7; IR (ATR) 3305, 2953, 2229, 2171, 1739, 1599, 1498, 
1279, 1241, 1094, 925 cm-1; HRMS (ESI) calcd for C15H21N2O6 (M+H
+) 325.1400, found 
325.1405  
Analytical data for 140 (single isomer): [α]D
21= -110.3 ± 0.1(c= 0.1, MeOH); mp = 94-95 °C; 1H 
NMR (400 MHz, CDCl3) δ 7.97 (d, J= 9.6 Hz, 1H), 6.42 (d, J= 9.6 Hz, 1H), 5.62 (m, 1H), 5.13 
(m, 2H), 4.37 (q, J= 7.2 Hz, 1H), 3.85 (s, 3H), 3.75 (s, 3H), 3.29 (t, J= 6.0 Hz, 1H), 2.45 (t, J= 
6.4 Hz, 2H), 1.43 (d, J= 6.4 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 173.7, 162.0, 155.2, 131.9, 
131.3, 126.6, 119.5, 115.8, 101.6, 77.2, 77.0, 76.8, 58.4, 56.0, 52.1, 50.2, 37.4, 20.4; IR (ATR) 
3305, 2953, 2848, 2531, 2196, 1735, 1596, 1497, 1276, 1237, 1014, 806 cm-1; HRMS (ESI) 
calcd for C15H21N2O6 (M+H
+) 325.1400, found 325.1405  
 
66 
 
 
To a stirred solution of 140 (1.028 g, 3.17 mmol) in DCM (32 mL) under nitrogen at 
ambient temperature was added pyridine (627 mg, 7.92 mmol). The resulting mixture was cooled 
to 0 °C and trifluoromethanesulfonic anhydride (1.073 g, 3.80 mmol) was added dropwise. After 
stirring for 6 h at 0 °C, the reaction was quenched with saturated NH4Cl solution (50 mL) and 
extracted with DCM (3×50 mL). The organic phases were combined, washed with 5% CuSO4 
solution (50 mL), dried (MgSO4) and filtered. The filtrate was evaporated under reduced 
pressure and the crude product was purified by chromatography (EtOAc/hexane/AcOH, 50:50:1) 
affording, in the order of elution, 142 (622 mg, 1.36 mmol, 43%) as yellow oil and 143 (640 mg, 
1.40 mmol, 44%) as yellow solid.  
Analytical data for 142: [α]D
21= -131.6 ± 0.1(c= 0.03, MeOH); 1H NMR (400 MHz, CDCl3) δ 
7.96 (d, J= 6.4 Hz, 1H), 6.94 (d, J= 6.0 Hz, 1H), 5.72 (m, 1H), 5.04 (m, 2H), 4.21 (q, J= 4.8 Hz, 
1H), 3.99 (s, 3H), 3.30 (s, 3H), 3.21 (t, J= 4.8 Hz, 1H), 2.33 (m, 2H), 1.51 (d, J= 4.8 Hz, 3H); 
13C NMR (150 MHz, CDCl3) δ 174.7, 163.3, 137.9, 135.9, 133.5, 128.4, 126.4, 121.4, 119.3, 
117.7, 117.2, 115.0, 110.1, 77.2, 77.0, 76.8, 60.1, 56.6, 51.3, 50.7, 38.2, 19.9; IR (ATR) 2954, 
2162, 1737, 1598, 1586, 1215  cm-1; HRMS (ESI) calcd for C16H20F3N2O8S (M+H
+) 457.0893, 
found 457.0910 
Analytical data for 143:[α]D
21= 27.9  ± 0.1(c= 0.04, MeOH); mp = 68-69 °C; 1H NMR (400 MHz, 
CDCl3) δ 8.04 (d, J= 6.0 Hz, 1H), 6.97 (d, J= 6.0 Hz, 1H), 5.51 (m, 1H), 5.08 (m, 2H), 4.34 (q, 
J= 4.8 Hz, 1H), 3.98(s, 3H), 3.74 (s, 3H), 3.01(dd, J= 6.0, 3.2 Hz, 1H), 2.55 (br s, 1H), 2.43 (m, 
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1H), 2.29 (m, 1H), 1.54 (d, J= 4.8 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 174.0, 162.8, 138.6, 
136.4, 133.6, 128.6, 126.6, 121.5, 119.3, 118.5, 117.2, 115.1, 109.9, 58.7, 56.5, 51.9, 49.5, 37.4, 
19.5; IR (ATR) 2953, 2229, 2031, 1740, 1531, 1348, 1216 cm-1; HRMS (ESI) calcd for 
C16H20F3N2O8S (M+H
+) 457.0893, found 457.0910  
 
 
Urotropine (382 mg, 2.73 mmol), bis(diphenylphospino)ferrocene (76 mg, 0.14 mmol), 
bis(dibenzylideneacetone)palladium (39 mg, 0.07 mmol) and N, N-dimethylacetamide (DMA) 
(10 mL) were added in a 50-mL round-bottomed flask. The mixture was stirred at ambient 
temperature for 5 minutes and a solution of 142 (622 mg, 1.36 mmol) in DMA (3.6 mL) was 
added under nitrogen. The resulting mixture was stirred at 90 °C for 48 h, cooled to ambient 
temperature and filtered through a pad of silica gel. The filtrate was washed with water (50 mL), 
dried (MgSO4), filtered and the solvents were removed under reduced pressure. Purification of 
the crude product by chromatography (EtOAc/hexanes, 4:6) gave 144 (220 mg, 0.72mmol, 53%) 
as yellow solid. 
Analytical data for 144: [α]D
21= -45.5 ± 0.1(c= 0.02, MeOH); mp = 78-80 °C, 1H NMR (400 
MHz, CDCl3) δ 7.57 (d, J= 8.8 Hz, 1H), 6.76 (d, J= 9.2 Hz, 1H), 5.06 (m, 4H), 4.09 (dd, J= 11.2, 
3.2 Hz, 1H), 3.86 (s, 3H), 3.73 (s, 3H), 3.04 (dd, J= 12.8, 3.2 Hz, 1H), 2.50 (br s, 1H), 2.25 (br s, 
1H), 1.37 (d, J= 7.2 Hz, 3H); 13C NMR (151 MHz, CDCl3) δ 173.4, 157.6, 144.1, 142.4, 137.3, 
133.8, 123.5, 117.9, 108.7, 77.2, 77.0, 76.8, 56.7, 56.1, 52.2, 46.9, 41.1, 17.0; IR (ATR) 2970, 
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2229, 1738, 1574, 1520, 1353, 1217 cm-1; HRMS (ESI) calcd for C15H19N2O5 (M+H
+) 307.1294, 
found 307.1292  
Urotropine (393 mg, 2.80 mmol), bis(diphenylphospino) ferrocene (78 mg, 0.14 mmol), 
bis(dibenzylideneacetone)palladium (40 mg, 0.07 mmol) and N, N-dimethylacetamide (DMA)(5 
mL) were added in a 50 mL round-bottomed flask. The mixture was stirred at ambient 
temperature for 10 minutes and a solution of 143 (640 mg, 1.40 mmol) in DMA (9 mL) was 
added under nitrogen. The resulting mixture was stirred at 90 °C for 48 h, cooled to ambient 
temperature and filtered through a pad of silica gel. The filtrate was washed with water (50 mL), 
dried (MgSO4), filtered and the solvents were removed under reduced pressure. Purification of 
the crude product by chromatography (EtOAc/hexanes, 4:6) gave 145 (183 mg, 0.60 mmol, 
43%) as yellow oil. 
Analytical data for 145: [α]D
21= 11.6 ± 0.1(c= 0.02, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.66 
(d, J= 9.2 Hz, 1H), 6.81 (d, J= 9.2 Hz, 1H), 5.14 (s, 1H), 4.92 (s, 1H), 4.60 (q, J= 6.4 Hz, 1H), 
3.86 (s, 3H), 3.69 (s, 3H), 3.53 (dd, J= 11.2, 6.4 Hz, 1H), 3.26 (ddt, J= 14.0, 6.0, 2.0 Hz, 1H), 
2.70 (dd, J= 13.6, 11.2 Hz, 1H), 1.29 (d, J= 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 174.0, 
159.2, 143.3, 140.7, 133.7, 132.1, 123.8, 118.3, 108.9, 77.3, 77.0, 76.7, 55.9, 54.6, 53.1, 52.1, 
41.4, 21.6; IR (ATR) 2971, 2205, 1737, 1712, 1518, 1219, 996 cm-1; HRMS (ESI) calcd for 
C15H19N2O5 (M+H
+) 307.1294, found 307.1291  
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A solution of 144 (106 mg, 0.35 mmol), bis(dibenzylideneacetone)palladium (14 mg, 
0.024 mmol), 1,3-bis(diphenylphosphino)propane (10 mg, 0.024 mmol), and 1,10-
phenanthroline (9 mg, 0.048 mmol) in anhydrous N, N-dimethylformamide (3.5 mL), in an ACE-
Glass pressure tube fitted with a pressure head, was saturated with carbon monoxide (4 cycles to 
6 atm of CO). The reaction mixture was stirred under CO (6 atm) at 120 °C for 72 h. The 
mixture was cooled to ambient temperature, filtered through a pad of silica gel and the filtrate 
was evaporated under reduced pressure. The resulting residue was purified by chromatography 
(hexanes/EtOAc, 1:1) to afford 146 (42 mg, 0.15 mmol, 44%) as yellow solid.  
Analytical data for 146: [α]D
21= 66.7 ± 0.1(c= 0.003, MeOH); mp= 126-127 °C, 1H NMR (400 
MHz, CDCl3) δ 8.05 (s, 1H), 7.16 (d, J= 8.8 Hz, 1H), 7.00 (s, 1H), 6.87 (d, J= 8.8 Hz, 1H), 4.99 
(q, J= 6.8 Hz, 1H), 4.17 (dd, J= 12.0, 2.8 Hz, 1H), 3.86 (s, 3H), 3.80 (s, 3H), 3.55 (dd, J= 15.2, 
2.8 Hz, 1H), 3.01 (m, 1H), 1.49 (d, J= 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 175.1, 149.0, 
132.6, 127.6, 124.9, 122.7, 112.5, 109.0, 108.5, 77.3, 77.0, 76.7, 57.1, 54.0, 52.3, 51.5, 34.6, 
19.9; IR (ATR) 3650, 3003, 2003, 1739, 1439, 1366, 1231, 1216 cm-1; HRMS (ESI) calcd for 
C15H19N2O3 (M+H
+) 275.1396, found 275.1401. 
  A solution of 145 (194 mg, 0.63 mmol), bis(dibenzylideneacetone)palladium (25 mg, 
0.044 mmol), 1,3- bis(diphenylphosphino)propane (18 mg, 0.044 mmol), and 1,10-
phenanthroline (16 mg, 0.089 mmol) in anhydrous N, N-dimethylformamide (6 mL), in an ACE-
Glass pressure tube fitted with a pressure head, was saturated with carbon monoxide (4 cycles to 
6 atm of CO). The reaction mixture was stirred under CO (6 atm) at 120 °C for 72 h. The 
mixture was cooled to ambient temperature, filtered through a pad of silica gel and the filtrate 
was evaporated under reduced pressure. The resulting residue was purified by chromatography 
(hexanes/EtOAc, 1:1) to afford 147 (75 mg, 0.27 mmol, 43%) as yellow solid.  
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Analytical data for 147: [α]D
21= -8.3 ± 0.1(c= 0.012, MeOH); mp= 141-143 °C, 1H NMR (400 
MHz, CDCl3) δ 7.96 (br s, 1H), 7.17 (d, J= 8.4 Hz, 1H), 7.00 (br s, 1H), 6.88 (d, J= 8.4 Hz, 1H), 
4.68 (q, J= 6.4 Hz, 1H), 3.87 (dd, J= 11.8, 2.8 Hz, 1H), 3.84 (s, 3H), 3.79 (s, 3H), 3.37 (dd, J= 
15.2, 2.8 Hz, 1H), 3.17 (m, 1H), 1.58 (d, J= 6.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 175.1, 
150.2, 132.7, 126.7, 125.7, 122.7, 112.8, 109.2, 109.2, 77.3, 77.0, 76.7, 59.0, 57.0, 54.0, 52.2, 
34.3, 23.7; IR (ATR) 3823, 3675, 3651, 1983, 1512, 1363, 1235; HRMS (ESI) calcd for 
C15H19N2O3 (M+H
+) 275.1396, found 275.1400  
 
1-[2-Hydroxy-6-(phenylmethoxy)phenyl]ethanone (148) (1.54 g, 6.3 mmol) was 
dissolved in glacial acetic acid (6.3 mL) and fuming nitric acid (0.6 mL) was added dropwise. 
The reaction mixture was stirred in a round-bottomed flask equipped with a drying tube (CaCl2) 
at room temperature for 40 min, and then at 50 °C for 16 h. The reaction mixture was poured into 
ice-water (40 mL) and extracted with EtOAc (3×40 mL). The combined organic layers were 
dried (MgSO4), filtered and solvents were removed under reduced pressure. The crude product 
was purified by chromatography (EtOAc/hexane, 2:8) affording, in the order of elution, 149 (96 
mg, 0.33 mmol, 5%) as a yellow solid and 150 (837 mg, 2.91 mmol, 46%) as yellow solid.  
Analytical data for 149: mp = 103-104 °C; 1H NMR (400 MHz, CDCl3) δ 13.13 (s, 1H), 8.10 (d, 
J= 12.0 Hz, 1H), 7.41 (m, 5H), 6.83 (d, J= 8.0 Hz, 1H), 5.06 (s, 2H), 2.60(s, 3H); 13C NMR (100 
MHz, CDCl3) δ 205.0, 167.3, 156.4, 134.6, 132.5, 129.2, 128.8, 128.7, 115.9, 114.5, 79.4, 32.8; 
IR (ATR) 2933, 2189, 1631, 1593, 1456, 1365, 1053, 969, 831cm-1; HRMS (ESI) calcd for 
C15H14NO5 (M+H
+) 288.0872, found 288.0867  
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Analytical data for 150: mp= 123-124 °C; 1H NMR (400 MHz, CDCl3) δ 12.38 (s, 1H), 8.16 (d, 
J= 9.6 Hz, 1H), 7.39 (m, 5H), 6.61 (d, J= 9.6 Hz, 1H), 5.23 (s, 2H), 2.58 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 201.3, 162.8, 155.9, 134.6, 130.0, 129.7, 128.9, 128.8, 127.4, 117.3, 104.0, 71.5, 
32.8; IR (ATR) 3071, 3039, 2628, 2193, 1623, 1588, 1367, 1319, 1246, 990, 777 cm-1; HRMS 
(ESI) calcd for C15H14NO5 (M+H
+) 288.0872, found 288.0868  
           
 
A solution of NH4OH and MeOH (1:1, v/v) (20 mL) was added dropwise to 150 (1.675 g, 
5.83 mmol) at ambient temperature. The resulting mixture was stirred for 12 h and the solvents 
were removed under reduced pressure to obtain yellow solid. This crude imine was dissolved in 
dichloromethane (30 mL), and (S)-2-amino-4-pentenoic acid methyl ester hydrochloride (1.931 
g, 11.66 mmol) and triethylamine (590 mg, 5.83 mmol) were added. The mixture was stirred 
under reflux for 12 h. Solvents were removed under reduced pressure and the crude product was 
dissolved in methanol (30 mL). To the stirred mixture at ambient temperature was added NaBH4 
(331 mg, 8.75 mmol) in one portion. The resulting mixture was stirred for 2 h at ambient 
temperature. The solvent was removed under reduced pressure and the crude product was 
purified by chromatography (EtOAc/hexane, 2:8) affording, in the order of elution, 152 (1.053 g, 
2.63 mmol, 45%) and 153 (798 mg, 1.99 mmol, 34%) as yellow solids.  
Analytical data for 152: [α]D
21= -2.1 ± 0.1(c= 0.05, MeOH); mp= 110-112 °C; 1H NMR (400 
MHz, CDCl3) δ 7.98 (d, J= 9.6 Hz, 1H), 7.39 (m, 5H), 6.55 (d, J= 9.2 Hz, 1H), 5.71 (m, 1H), 
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5.16 (m, 2H), 5.07 (m, 2H), 4.59 (q, J= 6.8 Hz, 1H), 3.47 (s, 3H), 3.37(t, J= 6.4 Hz, 1H), 2.42 (t, 
J= 6.8 Hz, 2H), 1.44 (d, J= 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 173.8, 162.2, 155.1, 
135.5, 132.9, 129.7, 128.9, 128.8, 128.5, 127.5, 127.4, 126.0, 118.7, 118.4, 104.0, 71.0, 58.9, 
51.6, 48.0, 36.8, 19.8.; IR (ATR) 3649, 2952, 2033, 1737, 1592, 1435, 1275, 1238 cm-1; HRMS 
(ESI) calcd for C21H25N2O6 (M+H
+) 401.1713, found 401.1717 
Analytical data for 153: [α]D
21= -21.6 ± 0.1(c= 0.05, MeOH); mp= 109-110 °C; 1H NMR (400 
MHz, CDCl3) δ 7.95 (d, J= 9.6 Hz, 1H), 7.38 (m, 5H), 6.48 (d, J= 9.6 Hz, 1H), 5.62 (m, 1H), 
5.15 (m, 4H), 4.49 (q, J= 6.8 Hz, 1H), 3.69 (s, 3H), 3.32 (t, J= 6.4 Hz, 1H), 2.45 (t, J= 6.0 Hz, 
2H), 1.48 (d, J= 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 173.7, 161.0, 155.3, 135.7, 131.8, 
128.9, 128.8, 128.4, 127.4, 127.0, 126.5, 119.6, 116.1, 110.0, 102.9, 70.6, 58.5, 52.1, 50.2, 37.4, 
20.4; IR (ATR) 3650, 3305, 2953, 2173, 1910, 1736, 1597, 1276 cm-1; HRMS (ESI) calcd for 
C21H25N2O6 (M+H
+) 401.1713, found 401.1718  
 
 
To a stirred solution of 152 (1.053 g, 2.63 mmol) in DCM (26 mL) under nitrogen at 
ambient temperature was added pyridine (520 mg, 6.58 mmol). The resulting mixture was cooled 
to 0 °C and trifluoromethanesulfonic anhydride (890 mg, 3.16 mmol) was added dropwise. After 
stirring for 4 h at 0 °C, the reaction was quenched with saturated NH4Cl solution (25 mL) and 
extracted with DCM (3×50 mL). The organic phases were combined, washed with 5% CuSO4 
solution (50 mL), dried (MgSO4) and filtered. The filtrate was evaporated under reduced 
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pressure and the crude product was purified by chromatography (EtOAc/hexane, 2:8) affording 
154 (1.223 g, 2.30 mmol, 87%) as yellow oil. 
Analytical data for 154: [α]D
21= 75.8 ± 0.1(c= 0.03, MeOH); 1H NMR (400 MHz, CDCl3) δ 7.98 
(d, J= 10.0 Hz, 1H), 7.48 (m, 5H), 7.03 (d, J= 9.2 Hz, 1H), 5.68 (m, 1H), 5.22 (s, 2H), 5.02 (m, 
2H), 4.24 (q, J= 7.2 Hz, 1H), 3.34 (s, 3H), 3.25 (t, J= 6.4 Hz, 1H), 2.83 (br s, 1H), 2.33(t, J= 6.4 
Hz, 2H), 1.51 (d, J= 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 174.8, 162.5, 138.0, 136.1, 
134.5, 133.2, 129.0, 129.0, 128.6, 128.2, 126.4, 123.0, 119.9, 117.9, 116.7, 113.5, 111.0, 77.3, 
77.0, 76.7, 72.1, 60.1, 51.4, 50.7, 38.2, 20.1; IR (ATR) 3464, 3004, 2949, 1737, 1433, 1365, 
1227 cm-1; HRMS (ESI) calcd for C22H24F3N2O8S (M+H
+) 533.1206, found 533.1230  
 
 
To a stirred solution of 153 (798 mg, 1.99 mmol) in DCM (20 mL) under nitrogen at 
ambient temperature was added pyridine (394 mg, 4.98 mmol). The resulting mixture was cooled 
to 0 °C and trifluoromethanesulfonic anhydride (675 mg, 2.39 mmol) was added dropwise. After 
stirring for 4 h at 0 °C, the reaction was quenched with saturated NH4Cl solution (25 mL) and 
extracted with DCM (3×50 mL). The organic phases were combined, washed with 5% CuSO4 
solution (50 mL), dried (MgSO4) and filtered. The filtrate was evaporated under reduced 
pressure and the crude product was purified by chromatography (EtOAc/hexanes, 2:8) affording 
155 (918 mg, 1.72 mmol, 87%) as yellow oil.  
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Analytical data for 155: [α]D
21= -2.7 ± 0.1(c= 0.04, MeOH); 1H NMR (400 MHz, CDCl3) δ 8.02 
(d, J= 9.2 Hz, 1H), 7.43 (m, 5H), 7.05 (d, J= 10.4 Hz, 1H), 5.47 (m, 1H), 5.21 (m, 2H), 4.96 (m, 
2H), 4.32 (q, J= 6.8 Hz, 1H), 3.70 (s, 3H), 3.05 (dd, J= 8.4, 5.6 Hz, 1H), 2.38 (m, 1H), 2.24 (m, 
1H), 1.56 (d, J= 8.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 173.9, 161.9, 138.6, 136.4, 134.2, 
133.3, 129.0, 129.0, 128.7, 127.6, 126.6, 123.0, 119.9, 118.6, 116.7, 113.5, 111.1, 71.8, 58.9, 
51.9, 49.4, 37.4, 19.6; IR (ATR) 3467, 3016, 2971, 2952, 1740, 1365, 1228, 1029  cm-1; HRMS 
(ESI) calcd for C22H24F3N2O8S (M+H
+) 533.1206, found 533.1234  
 
 
Urotropine (581 mg, 4.14 mmol), bis(diphenylphospino) ferrocene (115 mg, 0.21 mmol), 
bis(dibenzylideneacetone)palladium (60 mg, 0.10 mmol) and N,N-dimethylacetamide (DMA) (5 
mL) were added in a 50-mL round-bottomed flask. The mixture was stirred at ambient 
temperature for 10 minutes and a solution of 154 (1.103 g, 2.07 mmol) in DMA (15 mL) was 
added under nitrogen. The resulting mixture was stirred at 90 °C for 48 h, cooled to ambient 
temperature and filtered through a pad of silica gel. The filtrate was washed with brine (50 mL), 
dried (MgSO4), filtered and the solvents were removed under reduced pressure. Purification of 
the crude product by chromatography (EtOAc/hexanes, 4:6) gave 158 (414 mg, 1.08 mmol, 
52%) as yellow oil. 
Analytical data for 158: [α]D
21= -235.3 ± 0.1(c= 0.007, MeOH); 1H NMR (400 MHz, CDCl3) δ 
7.58 (d, J= 8.8 Hz, 1H), 7.37 (m, 5H), 6.84 (d, J= 9.2 Hz, 1H), 5.18 (m, 4H), 4.96 (s, 1H), 4.12 
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(dd, J= 11.2, 2.8 Hz, 1H), 3.76 (s, 3H), 3.09 (dd, J= 12.4, 3.2 Hz, 1H), 2.54 (br s, 1H), 2.08 (br s, 
1H), 1.42 (d, J= 7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 173.3, 156.6, 144.3, 142.3, 139.9, 
137.4, 135.8, 134.2, 128.7, 128.3, 127.1, 123.5, 118.0, 110.1, 77.3, 77.0, 76.7, 70.8, 56.6, 52.2, 
47.2, 41.0, 17.1; IR (ATR) 3462, 3015, 2971, 2946, 1738, 1365, 1217 cm-1; HRMS (ESI) calcd 
for C21H23N2O5 (M+H
+) 383.1607, found 383.1617  
 
Urotropine (483 mg, 3.45 mmol), bis(diphenylphospino) ferrocene (96 mg, 0.17 mmol), 
bis(dibenzylideneacetone)palladium (50 mg, 0.08 mmol) and N, N-dimethylacetamide (DMA) (5 
mL) were added in a 50-mL round-bottomed flask. The mixture was stirred at ambient 
temperature for 10 minutes and a solution of 155 (918 mg, 1.72 mmol) in DMA (12 mL) was 
added under nitrogen. The resulting mixture was stirred at 90 °C for 48 h, cooled to ambient 
temperature and filtered through a pad of silica gel. The filtrate was washed with brine (50 mL), 
dried (MgSO4), filtered and the solvents were removed under reduced pressure. Purification of 
the crude product by chromatography (EtOAc/hexanes, 4:6) gave 159 (303 mg, 0.79 mmol, 
46%) as yellow oil. 
Analytical data for 159: [α]D
21= -14.5 ± 0.1(c= 0.014, MeOH); 1H NMR (400 MHz, CDCl3) δ 
7.69 (d, J= 9.2 Hz, 1H), 7.37 (m, 5H), 6.90 (d, J= 9.2 Hz, 1H), 5.15 (m, 3H), 4.98 (s, 1H), 4.77 
(q, J= 6.4 Hz, 1H), 3.74 (s, 3H), 3.60 (dd, J= 11.2, 6.4 Hz, 1H), 3.32 (dd, J= 14.0, 6.4 Hz, 1H), 
2.75 (dd, J= 13.8, 11.6 Hz, 1H), 1.64 (br s, 1H), 1.38 (d, J= 6.4 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 174.1, 158.2, 143.6, 140.7, 135.6, 133.9, 132.5, 128.7, 128.3, 126.9, 123.9, 118.5, 
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110.1, 77.3, 77.0, 76.7, 70.5, 54.7, 53.3, 52.2, 41.5, 21.8; IR (ATR) 3464, 3349, 3005, 2971, 
1738, 1519, 1352, 1217 cm-1; HRMS (ESI) calcd for C21H23N2O5 (M+H
+) 383.1607, found 
383.1615  
 
A solution of 158 (75 mg, 0.196 mmol), bis(dibenzylideneacetone)palladium (8 mg, 
0.014 mmol), 1,3-bis(diphenylphosphino)propane (6 mg, 0.014 mmol), and 1,10-phenanthroline 
(5 mg, 0.027 mmol) in anhydrous N, N-dimethylformamide (2 mL), in an ACE-Glass pressure 
tube fitted with a pressure head, was saturated with carbon monoxide (4 cycles to 6 atm of CO). 
The reaction mixture was stirred under CO (6 atm) at 120 °C for 72 h. The mixture was cooled to 
ambient temperature, filtered through a pad of silica gel and the filtrate was evaporated under 
reduced pressure. The resulting residue was purified by chromatography (hexanes/EtOAc, 6:4) to 
afford 160 (50 mg, 0.143 mmol, 73%) as white solid.  
 Analytical data for 160: [α]D
21= +16.7 ± 0.1(c= 0.012, MeOH); mp= 163-164 °C, 1H NMR (400 
MHz, CDCl3) δ 8.19 (br s, 1H), 7.39 (m, 5H), 7.14 (d, J= 9.2 Hz, 1H), 6.98 (br s, 1H), 6.91 (d, 
J= 8.8 Hz, 1H), 5.12 (m, 3H), 4.20 (dd, J= 12.2, 2.8 Hz, 1H), 3.81(s, 3H), 3.56 (dd, J= 15.6, 2.4 
Hz, 1H), 3.03 (ddd, J= 15.4, 12.4, 1.6 Hz, 1H), 2.32 (br s, 2H), 1.55 (d, J= 6.8 Hz, 3H); 13C 
NMR (101 MHz, CDCl3) δ 175.0, 148.0, 138.1, 132.8, 128.4, 128.1, 127.6, 127.6, 127.2, 127.0, 
124.9, 122.8, 112.5, 109.9, 109.2, 77.3, 77.0, 76.7, 71.8, 54.0, 52.3, 51.6, 34.5, 20.1; IR (ATR) 
3823, 3675, 3651, 1983, 1512, 1363, 1235; HRMS (ESI) calcd for C21H23N2O3 (M+H
+) 
351.1709, found 351.1716  
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A solution of 159 (120 mg, 0.314 mmol), bis(dibenzylideneacetone)palladium (13 mg, 
0.022 mmol), 1,3-bis(diphenylphosphino)propane (9 mg, 0.022 mmol), and 1,10-phenanthroline 
(8 mg, 0.044 mmol) in anhydrous N,N-dimethylformamide (3.1 mL), in an ACE-Glass pressure 
tube fitted with a pressure head, was saturated with carbon monoxide (4 cycles to 6 atm of CO). 
The reaction mixture was stirred under CO (6 atm) at 120 °C for 72 h. The mixture was cooled to 
ambient temperature, filtered through a pad of silica gel and the filtrate was evaporated under 
reduced pressure. The resulting residue was purified by chromatography (hexanes/EtOAc, 6:4) to 
afford 161 (65 mg, 0.185 mmol, 59%) as white solid. 
Analytical data for 161: [α]D
21= -25.0 ± 0.1(c= 0.008, MeOH); mp = 151-152 °C; 1H NMR (400 
MHz, CDCl3) δ 7.92 (br s, 1H), 7.34 (m, 5H), 7.16 (d, J= 8.4 Hz, 1H), 7.02 (br s, 1H), 6.94 (d, 
J= 8.8 Hz, 1H), 5.09 (dd, J= 16.4, 12.0 Hz, 2H), 4.78 (q, J= 6.4 Hz, 1H), 3.89 (dd, J= 12.0, 2.8 
Hz, 1H), 3.79 (s, 3H), 3.39 (dd, J= 15.2, 2.8 Hz, 1H), 3.21 (ddd, J= 15.4, 11.6, 1.6 Hz, 1H), 1.62 
(d, J= 6.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 175.0, 149.2, 138.0, 132.9, 128.4, 127.6, 
127.4, 127.2, 125.8, 122.7, 113.0, 110.7, 109.3, 77.3, 77.0, 76.7, 72.1, 59.0, 53.9, 52.2, 34.1, 
23.9; IR (ATR) 3823, 3675, 3651, 1983, 1512, 1363, 1235; HRMS (ESI) calcd for C21H23N2O3 
(M+H+) 351.1709, found 351.1699  
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To a solution of 162 (50 mg, 0.14 mmol) in methanol in an ACE-Glass pressure tube was 
added Pd/C (10%) (7 mg, 0.007 mmol). The resulting mixture was saturated with hydrogen gas 
(3 cycles to 2.7 atm) and stirred at 60 °C for 12 h. The reaction mixture was filtered through 
celite and the filtrate obtained was concentrated under reduced pressure. Purification of the crude 
product using MeOH/CHCl3 (1:4) afforded 164 (30 mg, 0.12 mmol, 83%) as an amorphous 
white powder.  
Analytical data for 164: [α]D
21= -20.0 ± 0.1(c= 0.005, MeOH); mp = 168-170 °C (lit: 183-185 
°C) 1H NMR (400 MHz, DMSO-D6) δ 10.54 (br s, 1H), 8.44 (s, 1H), 7.02 (s, 1H), 6.98 (d, J= 8.4 
Hz, 1H), 6.62 (d, J= 8.4 Hz, 1H), 4.70 (q, J= 6.8 Hz, 1H), 3.95 (d, J= 10.8 Hz, 1H), 3.68 (s, 3H), 
3.32 (d, J= 14.8 Hz, 1H), 2.87 (dd, J= 14.4, 11.6 Hz, 1H), 1.34 (d, J= 6.8 Hz, 3H); 13C NMR 
(101 MHz, CDCl3) δ 175.0, 144.4, 132.4, 125.1, 125.0, 122.4, 112.6, 112.2, 109.3, 54.0, 52.3, 
51.5, 34.5, 19.5; IR (ATR) 3698, 3671, 3622, 2111, 1519, 1356, 1245; HRMS (ESI) calcd for 
C14H17N2O3 (M+H
+) 261.1239, found 261.1237  
      
To a solution of 163 (46 mg, 0.13 mmol) in methanol in an ACE-Glass pressure tube was 
added Pd/C (10%) (7 mg, 0.007 mmol). The resulting mixture was saturated with hydrogen gas 
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(3 cycles to 2.7 atm) and stirred at room temperature for 1 h. The reaction mixture was filtered 
through celite and the filtrate obtained was concentrated under reduced pressure. Purification of 
the crude product using MeOH/CHCl3 (1:4) afforded 165 (30 mg, 0.12 mmol, 88%) as an 
amorphous white powder.  
Analytical data for 165: [α]D
21= -40.0 ± 0.1(c= 0.005, MeOH); mp= 91-93 °C (lit: 80-83 °C) 1H 
NMR (400 MHz, CDCl3) δ 7.93 (brs, 1H), 7.07 (d, J= 8.8 Hz, 1H), 7.00 (s, 1H), 6.65 (d, J= 8.4 
Hz, 1H), 4.67 (q, J= 6.4 Hz, 1H), 3.87 (dd, J= 11.4, 2.8 Hz, 1H), 3.79 (s, 3H), 3.38 (dd, J= 14.8, 
2.8 Hz, 1H), 3.16 (ddd, J= 15.2, 11.8, 1.6 Hz, 1H), 1.64 (d, J= 6.4 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 175.0, 145.5, 132.5, 125.8, 123.9, 122.5, 112.9, 112.7, 109.4, 59.1, 54.0, 52.2, 34.5, 
23.2; IR (ATR) 3823, 3693, 3652, 2031, 1566, 1341, 1254; HRMS (ESI) calcd for C14H17N2O3 
(M+H+) 261.1239, found 261.1238 
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5.3 Supporting Information for Chapter 4: Aurantioclavine 
 
A solution of 2-hydroxy-3-nitroacetophenone 199 (513 mg, 2.83 mmol) in THF (15 mL) 
was added dropwise into a solution of LHMDS (1 M in THF) (11.3 mL, 11.3 mmol) at -78 °C 
under argon atmosphere. The resulting mixture was stirred at -78 °C for 1 h. To the stirred 
mixture was added acetone (2.1 mL, 28.32 mmol) dropwise and continued to stir for 3 h at -78 
°C before quenching with saturated NH4Cl solution (15 mL). The mixture was extracted with 
EtOAc (3×50 mL). The combined organic layers were dried (MgSO4), filtered and solvents were 
removed under reduced pressure. The crude product was purified by chromatography 
(MeOH/DCM, 1:99) affording, 200 (490 mg, 2.05 mmol, 72%) as a yellow oil.  
Analytical data for 200: 1H NMR (400 MHz, CDCl3) δ 12.66 (br s, 1H), 8.22 (dd, J= 8.4, 2.0 Hz, 
1H), 8.08 (dd, J= 8.0, 1.6 Hz, 1H), 7.05 (t, J= 8.4 Hz, 1H), 3.31 (br s, 1H), 3.25 (s, 2H), 1.37 (s, 
6H); 13C NMR (100 MHz, CDCl3) δ 204.7, 155.7, 137.2, 136.8, 131.2, 125.2, 118.7, 77.3, 77.0, 
76.7, 70.2, 51.3, 29.6; IR (ATR) 3857, 3676, 3652, 2243, 1734, 1556, 1345; HRMS (ESI) calcd 
for C11H14NO5 (M+H
+) 240.0872, found 240.0869. 
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To a solution of 200 (1.13 g, 3.86 mmol) in pyridine (7.7 mL) under a nitrogen 
atmosphere was added trifluoroacetic anhydride (1.1 mL, 7.72 mmol) at 0 °C. The resulting 
mixture was stirred 0 °C for 4 h. The solvents were removed under reduced pressure and the 
crude product was purified by chromatography (EtOAc/hexanes, 5:95) affording 201 (784 mg, 
3.54 mmol, 92%) as yellow solid.  
Analytical data for 201: mp= 70-71 °C; 1H NMR (400 MHz, CDCl3) δ 13.77(s, 1H), 8.13 (dd, J= 
8.0, 1.6 Hz, 1H), 8.04 (dd, J= 8.4, 1.6 Hz, 1H), 6.98 (t, J= 8.0 Hz, 1H), 6.78 (m, 1H), 2.27 (d, J= 
1.2 Hz, 3H), 2.09 (d, J= 1.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 194.5, 161.9, 157.0, 138.1, 
135.3, 130.9, 124.0, 119.7, 117.8, 28.5, 21.8; IR (ATR) 3035, 2961, 2022, 1763, 1596, 1312, 
1197cm-1; HRMS (ESI) calcd for C11H12NO4 (M+H
+) 222.0766, found 222.0762. 
 
To a solution of 201 (610 mg, 2.76 mmol) in acetone (28 mL) was added solid potassium 
carbonate (1.15 g, 8.29 mmol) and p-methoxybenzyl chloride (520 mg, 3.31 mmol). The 
resulting mixture was stirred under reflux for 54 h. After cooling at ambient temperature, the 
reaction mixture was filtered through celite. The solvents were removed from the filtrate under 
reduced pressure. Water (50 mL) was added to the crude residue and the resulting mixture was 
extracted with EtOAc (3×80 mL). Organic layers were combined and dried (MgSO4), filtered 
and the filtrate was evaporated under reduced pressure. The crude product was purified by 
chromatography (5% K2CO3 added to silica gel, EtOAc/hexane, 5:95) affording 203 (700 mg, 
2.05 mmol, 74%) as yellow oil.  
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Analytical data for 203: 1H NMR (400 MHz, DMSO-D6) δ 8.05 (dd, J= 8.0, 2.0 Hz, 1H), 7.78 
(dd, J= 7.6, 1.6 Hz, 1H), 7.43 (t, J= 8.0 Hz, 1H), 7.21 (m, 2H), 6.93 (m, 2H), 6.57 (m, 1H), 4.86 
(s, 2H), 3.76 (s, 3H), 2.20 (d, J= 1.2 Hz, 3H), 1.92 (d, J= 1.2 Hz, 3H); 13C NMR (101 MHz, 
DMSO-D6) δ 190.6, 160.0, 159.3, 149.0, 145.2, 138.0, 134.1, 130.7, 127.8, 127.5, 125.4, 124.2, 
114.3, 114.0, 78.6, 55.6, 28.0, 21.5; IR (ATR) 3041, 2974, 1898, 1740, 1586, 1336 cm-1; HRMS 
(ESI) calcd for C19H20NO5 (M+H
+) 342.1342, found 342.1336. 
 
To a mixture of 203 (360 mg, 1.05 mmol) in DCM (5 mL) was added 4-amino-1-butene 
(450 mg, 6.33 mmol). The resulting mixture was cooled to -78 °C and TiCl4 (1M in DCM) (1.2 
mL, 1.2 mmol) solution was added dropwise. After stirring at -78 °C for 4 h, NaBH4 (60 mg, 
1.58 mmol) and methanol (5 mL) were added. The resulting mixture was allowed to warm to 0°C 
and stirred for 1 h. To the stirred mixture was added 0.5N NaOH (20 mL) and extracted with 
EtOAc (3×50 mL). The combined organic layers were dried (MgSO4), filtered and solvents were 
removed under reduced pressure. The crude product was purified by chromatography 
(EtOAc/hexane, 2:8) affording 205 (126 mg, 0.46 mmol, 43%) as a yellow solid.  
Analytical data for 205: mp= 128-130 °C; δ 7.85 (dd, J= 8.4, 1.6 Hz, 1H), 7.29 (d, J= 7.6 Hz, 
1H), 6.77 (t, J= 7.6 Hz, 1H), 5.76 (m, 1H), 5.34 (dt, J= 9.6, 1.6 Hz, 1H), 5.12 (m, 2H), 4.74 (d, 
J= 9.2 Hz, 1H), 2.73 (m, 2H), 2.33 (m, 2H), 1.75 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 136.9, 
136.8, 135.0, 133.6, 129.9, 124.7, 123.3, 117.6, 117.5, 58.9, 45.5, 33.4, 25.8, 18.3; IR (ATR) 
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3352, 2973, 2221, 1833, 1586, 1456, 1243, 1053cm-1; HRMS (ESI) calcd for C15H21N2O3 
(M+H+) 277.1552, found 277.1551  
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1H and 13C NMR for Chapter 2: Cimitrypazepine and Fargesine 
 
 
Figure 9: 1H NMR of Compound 95 
92 
 
 
Figure 10: 13C NMR of Compound 95 
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Figure 11: 1H NMR of Compound 97 
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Figure 12: 13C NMR of Compound 97 
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Figure 13: 1H NMR of Compound 98 
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Figure 14: 13C NMR of Compound 98 
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Figure 15: 1H NMR of Compound 101 
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Figure 16: 13C NMR of Compound 101 
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Figure 17: 1H NMR of Compound 102 
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Figure 18: 13C NMR of Compound 102 
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Figure 19: 1H NMR of Compound 103 
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Figure 20: 13C NMR of Compound 103 
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Figure 21: 1H NMR of Compound 104 
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Figure 22: 13C NMR of Compound 104 
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Figure 23: 1H NMR of Compound 105 
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Figure 24: 13C NMR of Compound 105 
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Figure 25: 1H NMR of Compound 106 
 
 
 
108 
 
 
Figure 26: 13C NMR of Compound 106 
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Figure 27: 1H NMR of Compound 88 
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Figure 28: 13C NMR of Compound 88 
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Figure 29: 1H NMR of Compound 107 
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Figure 30: 13C NMR of Compound 107 
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1H and 13C NMR for Chapter 3: Hyrtioreticulins C & D
 
Figure 31: 1H NMR of Compound 127 
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Figure 32: 13C NMR of Compound 127 
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Figure 33: 1H NMR of Compound 128 
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Figure 34: 13C NMR of Compound 128 
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Figure 35: 13C NMR of Compound 128 
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Figure 36: COSY of Compound 128 
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Figure 37: 1H NMR of Compound 136 
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Figure 38: 13C NMR of Compound 136 
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Figure 39: 1H NMR of Compound 137 
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Figure 40: 13C NMR of Compound 137 
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Figure 41: 1H NMR of Compound 138 
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Figure 42: 13C NMR of Compound 138 
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Figure 43: 1H NMR of Compound 140 racemic mixture 
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Figure 44: 13C NMR of Compound 140 racemic mixture 
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Figure 45: 1H NMR of Compound 140 single isomer 
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Figure 46: 13C NMR of Compound 140 single isomer 
129 
 
 
Figure 47: 1H NMR of Compound 142 
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Figure 48: 13C NMR of Compound 142 
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Figure 49: 1H NMR of Compound 143 
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Figure 50: 13C NMR of Compound 143 
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Figure 51: 1H NMR of Compound 144 
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Figure 52: 13C NMR of Compound 144 
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Figure 53: 1H NMR of Compound 145 
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Figure 54: 13C NMR of Compound 145 
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Figure 55: 1H NMR of Compound 146 
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Figure 56: 13C NMR of Compound 146 
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Figure 57: 1H NMR of Compound 147 
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Figure 58: 13C NMR of Compound 147 
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Figure 59: 1H NMR of Compound 149 
142 
 
 
Figure 60: 13C NMR of Compound 149 
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Figure 61: 1H NMR of Compound 150 
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Figure 62: 13C NMR of Compound 150 
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Figure 63: 1H NMR of Compound 152 
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Figure 64: 13C NMR of Compound 152 
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Figure 65: 1H NMR of Compound 153 
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Figure 66: 13C NMR of Compound 153 
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Figure 67: 1H NMR of Compound 154 
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Figure 68: 13C NMR of Compound 154 
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Figure 69: 1H NMR of Compound 155 
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Figure 70: 13C NMR of Compound 155 
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Figure 71: 1H NMR of Compound 158 
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Figure 72: 13C NMR of Compound 158 
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Figure 73: 1H NMR of Compound 159 
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Figure 74: 13C NMR of Compound 159 
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Figure 75: 1H NMR of Compound 160 
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Figure 76: 13C NMR of Compound 160 
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Figure 77: 1H NMR of Compound 161 
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Figure 78: 13C NMR of Compound 161 
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Figure 79: 1H NMR of Compound 164 
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Figure 80: 13C NMR of Compound 164 
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Figure 81: 1H NMR of Compound 165 
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Figure 82: 13C NMR of Compound 165 
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1H and 13C NMR for Chapter 4: Aurantioclavine  
 
Figure 83: 1H NMR of Compound 200 
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Figure 84: 13C NMR of Compound 200 
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Figure 85: 1H NMR of Compound 201 
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Figure 86: 13C NMR of Compound 201 
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Figure 87: 1H NMR of Compound 203 
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Figure 88: 13C NMR of Compound 203 
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Figure 89: 1H NMR of Compound 205 
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Figure 90: 1H NMR of Compound 205 
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Figure 91: 1H NMR of Compound 205 
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Figure 92: 13C NMR of Compound 205 
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Figure 93: COSY of Compound 205 
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Figure 94: HSQC of Compound 205 
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Figure 95: NOE of Compound 205 
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Figure 96: NOE of Compound 205 
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Figure 97: NOE of Compound 205 
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Figure 98: HMBC of Compound 205 
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Figure 99: HMBC of Compound 205 
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Figure 100: HMBC of Compound 205 
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